 
Document Type:  Study Protocol  
Official Title:  An open -label, non -randomized, Phase I study to evaluate the effect 
of copanlisib (a single intravenous dose of  60 mg) on the 
pharmacokinetics (PK) and pharmacodynamics (PD) of m etformin 
(MATE2 -K substrate) in healthy vol unteers  
NCT N umber:  [STUDY_ID_REMOVED]  
Document D ate: 15 May 2018 
 
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 1of 63
1. Title page
An open -label , non -randomized ,Phase I study to evaluate the effect of copanlisib 
(asingle intravenous dose of 60 mg) on the pharmacokinetics (PK) and 
pharmacodynamics (PD) of metformin (MATE2 -K substrate) in healthy volunteers
Effect of 
copanlisib on metformin PK and PD
Test drug: Copanlisib / BAY 80 -6946
Study  purpose: To evaluate the effect of copanlisib on the PK and PD of 
metformin
Clinical study  phase: 1 Date: 15May 2018
Registration: Not applicable Version no.: 1.0
Sponsor’s study  no.:
19951
Sponsor: Bayer HealthCare Pharmaceuticals Inc., 100 Bayer 
Boulevard, P.O. Box 915, Whippany NJ 07981 -0915, USA
Sponsor’s medical expert:
Bayer AG
Drug Discovery , Pharmaceuticals
Clinical PD ONC I
Building P300 
13342 Berlin, German y
The study  will be conducted in compliance with the protocol, ICH
-GCP and any  applicable 
regulatory  requirements.
Confidential
The information provided in this document is strictly  confidential and is intended solely  
for the guidance of the clinical investigation.  Reproduction or disclosure of this 
document - whether in part or in full - to parties not associated with the clinic al 
investigation or its use for an y other purpose without the prior written consent of the 
sponsor is not permitted.
Throughout this document, sy mbols indicating proprietary  names ( , TM) may  not be 
display ed. Hence, the appearance of product names without these sy mbols does not imply  
that these names are not protected.
PPD
PPD
PPD
PPD
PPD
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 3of 63
Signature of principal investigator
The signatory  agrees to the content of the final clinical study  protocol as presented.
Name:
Affiliation:
Date: Signature:
Signed copies of this signature page are stored in the sponsor’s study  file and in the respective 
center’s investigator site file.
In the protocol document, this page may remain unsigned.
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 4of 63
2. Synopsis
Title An open -label, non -randomized, Phase I study to evaluate the effect of 
copanlisib (a single intraven ous dose of 60 mg) on the pharmacokinetics 
(PK) and pharmacodynamics (PD) of metformin (MATE2 -K substrate) in 
healthy volunteers
Short title Effect of Copanlisib on metformin PK and PD
Clinical study phase Phase 1
Study objectives The p rimary objective of this study is to :
Evaluate the effect of the co -administration of copanlisib on 
the PK of metformin
The s econdary objectives of this study are to :
Assess the safety of copanlisib when administered to healthy 
subjects in combination with metformin
Evalu ate the PD effect of copanlisib on metformin in terms of 
plasma lactate levels
Exploratory objectives of this study are to :
Assess additional copanlisib and metformin PK parameters
Assess additional PD parameters
Test drug BAY 80 -6946 (Copanlisib )
Nam e of active ingredient 2-amino-N-[7-methoxy -8-(3-morpholin -4-ylpropoxy) -2,3-
dihydroimidazo[1,2 -c]quinazolin -5-yl]pyrimidine -5-
carboxamidedihydrochloride (IUPAC)
Dose 60 mg
Route of administration Intravenous (i.v.)
Duration of treatm ent Single dose on Day 8
Interaction drug Metformin
Nam e of active ingredient Metformin hydrochloride
Dose 1000 m g tablet
Route of administration Oral
Duration of treatm ent Single dose on Day 1
Single dose on Day 8
Indication Not applicable
Diagnosis and main criteria for 
inclusion /exclusionHealthy subject s, aged 18 to 45 year s, with body  massindex of 18.0 to 
34.0 kg/m2, body weight ≥50 kg , creatinine clearance ≥ 90 mL/min using 
the Modification of Diet in Renal Disease (MDRD formula) , and a dequate 
end organ function .
Study design This study is a phase 1, non-random ized, single -center , open -label study to 
investigate the effect of copanlisib, a MATE2 -K inhibitor, on the PK and 
PD of metformin (a MATE2 -K substrate) in healthy subjects.
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 5of 63
Methodology Pharm acokin etics
Type of control Uncontrolled
Number of subjects 15 subjects ,to have at least 12 subjects valid for PK
Prim ary variables Primary variables:
 PK parameters : Cmax, AUC(0 -24) and AUC for metformin on 
Day 1 and Day 8
Time point/fram e of 
measurement for prim ary 
variable(s)Serial b lood samples for the determination of metformin PK parameters will 
be collected on Day 1 and Day 8 –pre dose and up to 24 h after drug 
administration
Plan for statistical analysis To investigate the primary objective of this study regarding the effect of 
copanlisib on metformin, an exploratory analysis of variance (ANOVA) 
with terms of treatment condition and subject w ill be performed on the 
natural logarithmic transformation of PK parameters (AUC, AUC (0-24)and 
Cmax) of metformin. The estimate and 90% confidence interval of the Day 8 
(with copanlisib) to Day 1 (without copanlisib) ratio of C max, AUC(0 -24) 
and AUC for metformin are derived by inverse transformation of the 
estimates and the 90% confidence interval of the least squares mean 
differences that are obtained from the model above.
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 6of 63
Table of contents
1.Title page ............................................................................................................................ 1
Signature of the sponsor’s medically responsible person ..................................................... 2
Signature of principal investigator
......................................................................................... 3
2.Synopsis .............................................................................................................................. 4
Table of tables ........................................................................................................................... 8
Table of figures ......................................................................................................................... 8
List of abbr eviations ................................................................................................................. 9
Definitions of terms ................................................................................................................ 12
3.
Introduction ..................................................................................................................... 13
3.1 Background .................................................................................................................... 13
3.2 Rationale of the study .................................................................................................... 15
3.3 Benefit -risk assessment .................................................................................................. 15
4.Study objectives ............................................................................................................... 17
5.Study design ..................................................................................................................... 17
6.Study pop ulation ............................................................................................................. 20
6.1 Inclusion criteria ............................................................................................................ 20
6.2 Exclusion criteria ........................................................................................................... 21
6.3 Justification of selection criteria .................................................................................... 23
6.4 Withdrawal of subjects from study ................................................................................ 23
6.4.1 Withdrawal ................................................................................................................. 23
6.4.2 Replac ement ............................................................................................................... 24
6.5
Subject identification ..................................................................................................... 24
7.Treatments ....................................................................................................................... 25
7.1 Treatments to be administered ....................................................................................... 25
7.2 Identity  of study  treatment ............................................................................................. 25
7.3 Treatment assignment .................................................................................................... 25
7.4
Dosage and administration............................................................................................. 26
7.5
Blinding ......................................................................................................................... 26
7.6 Drug logistics and accountability ................................................................................... 26
7.7 Treatment compliance .................................................................................................... 26
8.Non-study therapy ........................................................................................................... 27
8.1 Prior and concomitant therap y
....................................................................................... 27
8.2 Post-study  therapy .......................................................................................................... 27
9.Procedures and variables ............................................................................................... 27
9.1 Tabular schedule of evaluations .................................................................................... 27
9.2 Visit description ............................................................................................................. 27
9.2.1 Screening .................................................................................................................... 27
9.2.2 Pre-dose (Study  Day  
-1) ............................................................................................. 29
9.2.3 Randomization ............................................................................................................ 29
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 7of 63
9.2.4 Treatment Period ................................ ................................ ................................ ........ 29
9.2.5 End of treatment visit ................................................................................................. 32
9.2.6 Follow -
up ................................................................................................................... 32
9.2.7 Specia l conditions during the study ............................................................................ 32
9.3 Population characteristics .............................................................................................. 33
9.3.1 Demographic .............................................................................................................. 33
9.3.2 Medi cal history ........................................................................................................... 34
9.3.3 Other baseline characteristics ..................................................................................... 34
9.4 Efficacy .......................................................................................................................... 34
9.5 Pharmacokine tics / pharmacody namics ......................................................................... 34
9.5.1 Pharmacokinetics ........................................................................................................ 34
9.5.2 Pharmacod ynamics ..................................................................................................... 36
9.6 Safety............................................................................................................................. 37
9.6.1 Adverse events ............................................................................................................ 37
9.6.2 Pregnancies ................................................................................................................. 45
9.6.3 Further safet y
.............................................................................................................. 45
9.7
Other procedures and variables...................................................................................... 46
9.8
Appropriateness of procedures / measurements ............................................................ 46
10.Statistical methods and determination of sample size ................................................. 47
10.1 General considerations ................................................................................................... 47
10.2 Analy sis sets .................................................................................................................. 47
10.3 Variables and planned statistical anal yses..................................................................... 47
10.4 Determination of sample size ......................................................................................... 48
10.5 Planned interim anal yses............................................................................................... 49
11.
Data handling and quality assurance ............................................................................ 49
11.1
Data recording................................................................................................................ 49
11.2 Monitoring ..................................................................................................................... 50
11.3 Data processing .............................................................................................................. 51
11.4 Missing data ................................................................................................................... 51
11.5
Audit and inspection ...................................................................................................... 51
11.6 Archiving ....................................................................................................................... 51
12.Premature termination of the study .............................................................................. 52
13.Ethical and legal aspects ................................................................................................. 53
13.1 Investigator(s) and other study  personnel
...................................................................... 53
13.2 Funding and financial disclosure ................................................................................... 53
13.3 Ethical and legal conduct of the study ........................................................................... 54
13.4
Subject information and consent.................................................................................... 54
13.5 Publication policy  and use of data ................................................................................. 55
13.6 Compensation for health damage of subjects / insurance .............................................. 56
13.7 Confidentiality ............................................................................................................... 56
14.Reference list .................................................................................................................... 56
15.Protocol amendments ...................................................................................................... 57
16.Appendices ....................................................................................................................... 58
16.1 Study  flow chart ............................................................................................................. 58
16.2 Laboratory  anal yses....................................................................................................... 60
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 8of 63
16.3 Concomitant medication NOT permitted (or to be taken with caution) during 
screening and treatment phase of the stud y ................................................................... 62
16.4 Estimation of glomerular filtration rate (eGFR) using modification of diet in renal 
disease ............................................................................................................................ 63
Table of tables
Table 3
–1:Most common AEs (all Grade ≥2%) in copanlisib monotherapy  studies in cancer 
patients after a single dose of copanlisib ............................................................... 16
Table 5
–1: Objectives and related variables............................................................................ 19
Table 7–1: Treatments to be administered ............................................................................... 25
Table 9
–1: Restrictions during the stud y.................................................................................. 33
Table 9
–2: PK sampling and dosing time points for metformin and copanlisib in plasma ..... 35
Table 9–3: Urine sample collection for metformin PK evaluation on Day s 1 and 8 ............... 36
Table 9–4: Pharmacod ynamic assessment and rationale ......................................................... 37
Table 9
–5: Pharmacod ynamic sampling .................................................................................. 37
Table 9
–6: Management of transient post -infusion glucose increases ..................................... 44
Table 10
–1: 90% Confidence interval for metformin with N=12 ............................................ 49
Table 16
–1: Study  flow chart ................................................................................................... 58
Table 16
–2: Schedule of evaluations: In -house treatment period ......................................... 59
Table 16
–3: Parameters of laboratory  anal yses........................................................................ 61
Table of figures
Figure 3 -1: Key  major known transporters involved in the absorption and urinary  excretion of 
metformin .............................................................................................................. 15
Figure 5 -1: Flow chart of study  design .................................................................................... 18
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 9of 63
List of abbreviations
AE adverse event
AE,ur(0-24) amount excreted into urine from 0 to 24 h
%A E,ur(0-24) Percentage of drug excreted in the urine between 0 and 24 hours
AE,ur(t1-t2) amount excreted into urine from t1 to t2, where t1 and t2 are the start and 
the stop times of the urine collection interval
%A E,ur(t1-t2) Percentage of drug excreted in the urine between t1 and t2, where t1 and t2 
are the start and the stop times of the urine collection interval
AKT protein kinase B
ALT alanine aminotransferas e(also: glutamate p yruvate transaminase, GPT)
ANOVA analysis of variance
anti-HIV 1+2 human immunodeficiency virus 1 and 2 antibody
AP alkaline phosphatase
A
ST aspartate aminotransferase (also: glutamic -oxaloacetic transaminase, GOT)
AUC area under the concentration vs. time curve from zero to infinity  after single 
dose
AUC(0 -24) AUC from time 0 to 24 hours
BCRP breast cancer resistance protein
BMI body  mass index: weight [kg] / (height [m])²
BP blood pressure
C24h concentration at 24 hours
C6h concentration at 6 hours
CI confidence interval
CL/F total body  clearance of drug calculated after extravascular administration 
(e.g. apparent oral clearance)
CL R renal body  clearance of drug
Cmax maximum observed drug concentration in measured matrix after single 
dose administration
CRF case report form
CRO contract research organization
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 10of 63
CTCAE common terminology  criteria for AEs
CV coefficient of variation
CYP cytochrome P450
DDI drug-drug interaction
dL deciliter
ECG electrocardiogram
EDC electronic data capture
eGFR estimated glomerular filtration rate
EOT End of Treatment
EudraCT EU data repository  for clinical trials
FDA Food and Drug Administration
GCP Good Clinical Practice
GFR glomerular filtration rate
GGT gamma glutam yl transpeptidase (orgamma -glutamy l transferase )
GMP Good Manufacturing Practice
GSK3 glycogen s ynthase kinase 3
HbA1c glycated hemoglobin
HBsAg Hepatitis B surface antigen
HCV -Ab hepatitis C virus antibodies
HDL high-densit y lipoprotein
HIV human immunodeficiency virus
IB investigator ’s brochure
IC50 50% inhibition
ICH International Conference on Harmonization
INR international normalized ratio
i.e. id est (that is)
IEC independent ethics committee
IR insulin receptor
IRB institutional review board
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 11of 63
IUD intrauterine device
IUPAC 2-amino -N-[7-methoxy -8-(3-morpholin -4-ylpropoxy ) -2,3-
dihydroimidazo[1,2 -c]quinazolin -
5-yl]pyrimidine - 5-
carboxamidedihy drochloride
IUS intrauterine hormone -releasing s ystem
i.v. intravenous
kg kilogram
L liter
LDL low-density  lipoprotein
LLOQ lower limit of quantitation
L
SLV last subject last visit
MATE multidrug and toxin extrusion transporter
MDRD Modification of Diet in Renal Disease
MedDRA medical dictionary  for regulatory  activities
mmHg millimeter of mercury
mTOR mammalian target of rapamy cin
n number
OAT organic anion transport er
OATP organic anion- transporting pol ypeptide
OCT organic cation transporter
OTC over-the-counter
pAKT phosphory lated protein kinase B (phospho -AKT)
PD pharmacod ynamic ( s)
P-gp permeability  glycoprotein
PK pharmacokinetic ( s)
PI3K phosphatidylinositol 3 -kinase
PR PR interval in ECG
PT preferred term
QA Quality  Assurance
QC quality  control
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 12of 63
QRS QRS duration in ECG
QT QT interval in ECG
QTc QT interval corrected for heart rate
QTcB QT interval corrected according to Bazett’s formula
RR RR interval in ECG
RTK receptor ty rosine kinase
SAE serious adverse event
SAP Statistical Analy sis Plan
SD standard deviation
SUSAR suspected unexpected serious adverse reaction
TEAE treatment emergent AE
t1/2 half-life associated with the terminal slope
tmax time to reach C max
ULN upper limit of norm (upper limit of normal laboratory  values)
US(A) United States (of America)
VZ/F apparent volume of distribution during terminal phase after extravascular 
administration
Definitions of terms
BAY no. BAY number is the main identifier for compounds within the Bay er 
Pharmaceuticals Organization
RAVE validated electronic data capture s ystem
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 13of 63
3. Introduction
3.1 Background
Copanlisib characteristics
Further details can be found in the latest available version of the investigator’s brochure (IB), 
which contains comprehensive information on the study  drug.
Copanlisib (BAY 80 -6946) was approved viaaccelerated approval in the US on 14SEP 2017,
as a monotherap ytreatment inadult patients with relapsed follicular l ymphoma who have 
received 2 prior s ystemic therapies. 
Copanlisib is an inhibitor of phosphatidy linositol
-3-kinase (PI3K) with inhibitory  activit y 
predominantly  against PI3K -α and PI3K -δ isoforms expressed in malignant B cells. 
Copanlisib inhibits the cataly tic activity  of the class I PI3K-α, -β, -γ, and - δ isoforms wi th 
biochemical concentrations required for 50% inhibition (I C50) of 0.5, 3.7, 6.4, and 0.7 nM, 
respectivel y.  Copanlisib is being further developed for the treatment of advanced and 
refractory  malignancies either as a single agent or in combination with ot her investigational 
agents. Copanlisib is the active ingredient (free base) of BAY 84- 1236, the dihy drochloride 
salt, which for clinical use is formulated as an intravenous (i.v.) drug product solution.
Therecommended approved dose of copanlisib is 60 mg administered as a 1 -hour i.v.
infusion on Days 1, 8, and 15 of a 28 -day treatment cy cle on an intermittent schedule (three 
weeks on and one week off).
Safety and efficacy
As of 21 JUN 2017 , approximately  772 patients with advanced cancer have been treated with 
copanlisib as single agent or in combination with other anticancer drugs in Phase 1, 2 and 3 
studies. C
opanlisib has also been studied in healthy  volunteers. Amass balance study  was
conducted in healthy  subjects (Study 16353): 6 healthy  male subjects were treated with a 
single i.v. administration of 12 mg [14C]copanlisib.  An additional ongoing Phase 1study  
(18041) is being conducted in non- cancer subjects to assess the effect of hepatic and renal 
impairment on the pharmacokinetic s (PK)of a single 12 mg dose of copanlisib in comparison 
to healthy
 subjects.
Based on the recent accelerated approval of copanlisib, the common adverse reactions based 
on the pooled safet y analy sis in more than 20% of patients were: h yperglycemia, diarrhea, 
fatigu e, hypertension, leukopenia, neutropenia, nausea, lower respiratory tract infections, and 
thrombocy topenia. The most common grade 3- 4 adverse reactions include hy pergly cemia, 
leukopenia, h ypertension, neutropenia, and lower respiratory tract infections. Serious 
non-infectious pneumonitis occurred in 6% of patients .
Clinical efficacy  has been demonstrated based on results in 104 patients with relapsed 
follicular ly mphoma enrolled in an open -label, single -arm, multi -center, P hase 2 study
(Study 16349) in which p atients received 0.8 mg/kg or 60 mg of copanlisib by  i.v.infusion on 
Days 1, 8, and 15 of a 28
-day treatment cy cle. The objective response rate was 5 9% with 
estimated median response duration of 12.2 m onths. The complete response rate was 14.4% 
andpartial response rate was 44.2% .
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 14of 63
Copanlisib clinical pharmacology summary
Copanlisib plasma exposure (C maxand AUC) increased in a dose -proportional manner over an 
absolute dose range of 5 to 93 mg (0.08 to 1.55 times the appr oved recommended dose of 
60 m g) with a terminal elimination half -life of 39.1 hours .There is no time -dependency  and 
no accumulation in the PKof copanlisib with the weekl y intermittent dosing schedule .
Copanlisib is eliminated predominantly  via feces (64% of the administrative radi oactive dose 
mean recovery  with 30% unchanged copanlisib) compared to urine (22% mean recovery  with 
15% unchanged copanlisib) ; 41% of the dose was excreted as oxidative metabolites. The 
minor M -1 metabolite accounts only  for 5% of total radioactivit y AUC with pharmacological 
activity  comparable to copanlisib .Population PK anal yses showed that age (20 to 90 y ears), 
gender, race, smoking status, body  weight (41 to 130 kg), mild hepatic impairment, and mild 
to moderate renal impairment had no clinically  significant effect on the PK of copanlisib. 
Based on the preliminary categorical anal yses and the central tendency , copanlisib does not 
prolong the QT/QTc interval.
Copanlisib metabolism is predominantly  mediated by  cytochrome P450 (CYP) 3A4 ( >90% ) 
and to a minor extent by CYP1A1 (<10%) . Concomitant use of copanlisib with strong 
CYP3A inducers may  decrease copanlisib AUC and C maxvalues, and should be avoided. 
Concomitant use of copanlisib with strong CYP3A inhibitors increases copanlisib AUC, and a 
dosage reduction to 45 mg is advised if patients require strong CYP3A inhibitors . Copanlisib 
has low potential for DDI as perpetrator to influence the PK of other drugs by  inhibition or 
induction of metabolizing enz ymes (CYPs, uridine 5'- diphospho- glucuronosy ltransferase 
[UGT]) and transport proteins . Copanlisib is an inhibitor of multidrug and toxin extrusion 
transporter (MATE) MATE2 -K transporter at the clinical relevant concentrations. Copanlisib 
is a weak substrate of permeability  glycoprotein (P -gp), and breast cancer resistance protein 
(BCRP), and not a substrate for the efflux transporters MATE1 and MATE2 -K or the uptake 
transporters organic cation transporter (OCT) , organic anion transporter (OAT) and organic 
anion
-transporting pol ypeptide (OATP) .
Metformin ( probe drug-s ubstrate )
Metformin, a commonly  used oral glucose
-lowering drug for t ype II diabetes mellitus, is not 
metabolized in the liver. Metformin is widely  used as a substrate drug for OCT1, OCT2 and 
OCT3 mediated transport ,and for human MATE1 and MATE2- K mediated transport ,for 
evaluating the e ffect of an inhibitor drug on OCT and MATE2- K transporters activities in 
vivo (Figure 3-1 ) (1).  Following a single oral dose, peak metformin concentrations are 
achieved at 1to 2hours with a half -life ofabout 5 hours .Metformin is excreted into urine 
(~90% within 12 hours), secreted b y renal tubules with a population mean for renal clearance 
(CLR) ~450mL/min. The extent of pla sma protein binding of metformin isminimal . Dosage 
range is between 1 to 3g/day  (given up to 3 times a day ).
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 15of 63
Figure 3-1: Key major known transporters involved in the absorption and urinary 
excretion of metformin
MATE=multidrug and toxin extrusion transporter; OCT=organic cation transporter
Graham et al, 2011(2)
3.2 Rationale of the study
In vitro ,copanlisib showed a concentration -dependent inh ibition of the renal transporter 
MATE2 -K using metformin as a probe substrate , with Cmax copanlisib /IC50= 1.0 µM/0.089 µM
~ 11; which is greater than the recommended cut- off (C max/IC50≥ 0.1) for conducting a 
clinical drug-drug interaction (DDI)study  according to the Food and Drug Administration
(FDA )DDI draft guidance. Furthermore, metform in,a MATE2 -K substrate , is sometimes 
used as a concomitant medicine in clinical stud iesto control high blood sugar ( transient 
hypergly cemia) observed with copanlisib
. This is a known target effect due to the inhibition 
of the PI 3K–α isoform pathway  by copanlisib. Metformin is eliminated unchanged b y renal 
mechanisms, and while the liver is important for the
pharmacologic activity  of metformin, 
biliary  excretion of metformin is negligible (2).The co -administration of metformin and 
copanlisib might reduce the CL Rof metformin, may increase the metformin concentration in 
the kidney , and potentially lead to increased plasma concen trations. Therefore, this study  will 
be conducted to evaluate the effects of copanlisib as a perpetrator using the full 
recommended 
approved dose of 60 mg on the PK and pharmacody namics (PD) of metformin (victim drug) 
in order to provide guidance for d ruglabeling recommendations when copanlisib is 
concomitant lyadministrated with sensitive MATE2 -K substrate .
3.3 Benefit-risk assessment
Copanlisib full dose of 60 mg hasnotbeen used previously  in healthy  volunteers. In the 
context of this study ,a full dose is required to truly  assess the effect of copanlisib as a strong 
inhibitor of MATE2-K according to the FDA DDI guidance, 2017. A 12 mg dose will not be 
appropriate to full y characterize the clinical DDI effect due to copanlisib acting as a 
perpetrator of MATE2 -
K.No serious adverse events ( SAEs )or adverse events ( AEs)of 
severit y >Grade 3 were reported from Study 16353 (mass balance study  in healthy  subjects 
using a copanlisib dose of 12 mg(3)). Preliminary  safet y data in the ongoing S tudy 18041 
(copanlisib single dose of 12 mg)in3 renal and 1 hepatic impaired subjects showed no 
AEs
(clinical or laboratory )to date.

Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 16of 63
The data from monotherapy  studies includ ea total of 286 cancer patients who experienced 
AEs following the first dose of 60 mg or 0.8 mg/kg(equivalent to approximately  60mg 
absolute dose), but before the second dose on Day 8. The most common (all Grade ≥2%) AEs
are identified in Table 3–1.
Table 3
–1: Most common A Es (all Grade ≥2%) in copanlisib monotherapy 
studies in cancer patients after a single dose of copanlisib
Preferred term (PT) CTCA E Grade 3
(N=286)CTCA E Grade 4
(N=286)CTCA E All Grades
(N=286)
Hyperglycaemia 20.3% 0.7% 45.80%
Hypertension 14.7% 0 24.48%
Nausea 0.7% 0 12.94%
Diarrhoea 0.7% 0 9.09%
Vomiting 0.3% 0 3.50%
Constipation 0 0 3.15%
Pyrexia 1.0% 0 2.80%
Fatigue 0 0 2.45%
Chills 0 0 2.10%
Headache 0 0 2.10%
CTCAE = common terminology criteria for AEs
Copanlisib has notbeen associated with severe h ypersensitivity  reactions and no 
contra indications for copanlisib were identified from pooled safet y data. The treatment 
emergent AEs ( TEAEs )following first dose of copanlisib included transient and 
asymptomatic hy pergl ycemia and h ypertension; in addition to gastrointestinal and general 
disorder events. There is no evidence to su ggest the safet y profile would be associated with 
more severe known toxicities or new safety  issues in healthy  volunteers compared to the 
patient population studied in the clinical trials. Considering safet y data from the completed 
healthy  volunteer study  and manageable AEs, with absence of severe hy persensitivity  related 
events associated with the 
first dose of cop anlisib in monotherapy , a single dose of 60 mg 
copanlisib is considered safe for the proposed study  and would not expose subjects to severe 
or unmanageable toxicities .
The monitoring and treatment of AEs will ensure that subjects will not be exposed to undue 
risk and the inclusion and exclusion criteria will ensure that subjects who might be 
predisposed to higher risk of dr ug-related TEAEs are excluded .
The toxicologic and safety -pharmacologic investigations identified the need for monitoring 
cardiovascular, hepatic, renal and metabolic functions during earl y studies in humans. 
Copanlisib is non -genotoxic in vitro and in vivo. Practicall y, this will be addressed in this 
study  through ph ysical examinations including check of vital signs, electrocardiograms 
(
ECGs) , monitoring of clinical chemistry  laboratory , and in particular, close monito ring of 
glucose and blood pressure following the infusion.
Because changes in the reproductive s ystem and adverse effects on development, including 
embry o-lethalit y and teratogenicit y, cannot be excluded, women of childbearing potential and 
men must agree to use highl y effective contraception from signing of the informed consent 
form until at least 3months after copanlisib dosing. The investigator or a designated 
associate is requested to advise the subje ct how to achieve highl y effective contraception.
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 17of 63
Metformin has a very  broad therapeutic range with a low risk of overlapping toxicities. For 
full details on metformin, please refer to the current prescribing information / Summary  of 
Product Characteristi cs (SmPC).
Study subjects are not expected to gain an ydirect benefit from the stud y, since they  will have 
no malignancies susceptible t
orespond to copanlisib. However, the benefit of this trial will 
be the generation of further information on the effect s of copanlisib on metformin with
regards to PK and PD. These data will provide guidance for drug labeling recommendations 
when copanlisib is concomitant lyadministrated with sensitive MATE2 -K substrate , if needed . 
This is required as a post marketing requirement after the accelerated approval of copanlisib 
on 14 SEP 2017.
4. Study objectives
The primary  objective of this study  is to
Evaluate the effect of the co -administration of copanlisib on the 
PKof metformin
The second ary objecti vesof this study  are to
Assess the safet y of copanlisib when administered to healthy  subjects in 
combination with metformin
Evaluate the PD effect of copanlisib
onmetformin in terms of plasma lactate levels
Exploratory objective sof this study  are to
Assess additional copanlisib and metformin PK parameters
Assess additional PD parameters
5. Study design
Design overview
This study  is a phase 1,non-randomized, single -center, open -label study  to investigate the 
effect of copanlisib, a MATE2- K inhibitor, on the PK and PD of metformin in healthy  
subjects
.
A total of approximately  15 subjects between the ages of 18 to 45 years will be enrolled , to 
achieve 12 evaluable subjects . All subjects will receive a single dose of metformin 1000 mg 
on Day s 1 an d 8 in a fasting state.  Subjects will also receive a single i.v.dose of 60 mg 
copanlisib on Day  8 as part of the combination with metformin (Figure 5-1). After the first 
dose of metformin, there will be a 7 -day wash -out before the second dose of metformin with 
copanlisib on Day 8,to assess the effect of copanlisib as a perpetrator on metformin (victim 
drug). Dosing of both drugs will be done at the site. Subjects will need to fast overnight 
before metformin administration on Day s1 and 8. They  will continue fasting until 3 hours 
after metformin dosing and will then be given a low -carboh ydrate meal (eggs, cheese and/or 
plain y ogurt, vegetables, meat ).On Day  8, metformin will be given just before the start of the 
copanlisib infusion.  No i.v.glucose preparations should be administered on the day s of 
copanlisib i.v. infusion due to the known transient glucose elevation after copanlisib
administration related to the PI 3K pathway .
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 18of 63
Following each metformin dose, subjects will be asked to drink 8 oz (~237 mL) of water 
every  2hours during waking hours to maintain urine flow and pH.
Blood samples will be collected pr e-and pos t-dose, and uri ne samples will be collected up to 
24hours for metformin; blood samples will be collected up to 24 hours for copanlisib. 
Additional blood samples 
will be collected up to 24 hours after each dose of metformin for 
the PD evaluations.
Subjects will stay  in-house at the study  site from approximately  12hours before until 
24hours after each dose.
An end of treatment (EOT) visit will be conducted 7 to 14 day s after copanlisib dosing.
Follow -
up will be conducted 30 to 35 daysafter copanlisib dosing .This follow - up will be 
conducted b y telephone, unless an in -house visit is clinically  indicated.
Figure 5-1: Flow chart of study design
Screening
(within 
28days of 
first dose)Day 1 Day 8 Day 15-22 Day 38-43
Metformin 
1000 mg oralDays 2 -7
WashoutMetformin 
1000 mg oral
+
Copanlisib 
60mg i.v. 1 hour 
infusionEOT visit
(7-14days 
after 
copanlisib 
dosing)Follow -up 
phone call / 
visit
(30-35days 
after 
copanlisib 
dosing)
Intensive
PK and PD 
sampling for
metforminIntensive
PK and PD 
sampling for 
both drugs
EOT = End of treatment visit
The copanlisib dose for this study is the standard dose recently  approved and also used in 
Phase 1, 2 and 3 studies across the copanlisib development program: 60 mg i.v. infusion 
administered intermittently  on D ays 1, 8 and 15 of a 28 -day cy cle. The standard dose will be 
used to maximize the potential for a clinical impact of MATE2 -K inhibition by  copanlisib . 
The metformin dose is 1000 mg. The marketed drugs used in this study  will be administered 
at doses according to their approved label.
The variables related to each study objective are shown in Table 5–1.
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 19of 63
Table 5–1: Objectives and related variables
Objective Variable Section
Primary
To evaluate the effect of the 
co-administration of copanlisib 
on the PK of metforminPK parameters: Cmax, AUC(0 -24) 
and AUC for metformin on Day 1 
and Day 8See Section 9.5.1
Secondary
To assess the safety  of 
copanlisib when administered 
to healthy subjects in 
combination with metformin
To evaluate the PD effect of 
copanlisib on metformin in 
terms of plasma lactate levelsFrequenc y/severit y of treatment 
emergent AEs
PD parameters: plasma lactate 
levels and maximum change from 
baseline on Day 1 and Day 8See Section 9.6
See Section 9.5.2
Exploratory
To assess additional copanlisib 
and metformin PK parametersMetformin:
Day 1 and Day 8:
%AE,ur, AE,ur, %AE,ur(t1 -t2), 
AE,ur(t1- t2) where t1 and t2 are the 
start and the stop times of the urine 
collection interval
tmax, VZ/F, CL/F and t1/2; and CLR 
(calculated as CLR = 
AE,ur(0- 24)/AUC(0 -24))
Copanlisib:
Day 8:
Cmax, tmax, C6h, C24h and AUC(0 -
24)See Section 9.5.1
To assess additional PD 
parametersGlucose, insulin and C -peptide on 
Day 1 and Day 8See Section 9.5.2
Justification of the design
For stud y objectives please see Section 4and Table 5–1above .
This study  will investigate the effect of copanlisib, a MATE2 -K inhibitor, on the PK and PD 
of metformin (substrate drug of MATE2 -K) in healthy  subjects.
The PK measurements are the primary  focus of the study , therefore a no n-randomized, open -
label, single group design was considered adequate . Blinding procedures are not required in 
this study  as the PK parameters will not be affected by  either the subjects or the 
investigator(s).
The rationale for the use of metformin is pr ovided in Section 3.2. The metformin dose of 
1000 mg is in the range of approved clinical dose of metformin and similar to previous DDI 
studies with metformin as a victim drug (4). The rationale fo r the choice of copanlisib dose is 
provided in Section 3.3. The choice of regimen/schedule of administration is in accordance 
with the respective a pproved label for copanlisib and metformin.
It was chosen to conduct this study  in healthy  subjects because copanlisib is considered to be 
non-genotoxic in vitro and in vivo, and safe for the proposed stud y. Futhermore, previous 
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 20of 63
studies have alread y been conducted with cop anlisib in healthy  subjects; see Section 3.3for 
further details. See also Section 6.3for the justification of selection criteria.
The rationale for the choice of PD parameters is provided in Section 9.5.2 .
For handling of missing data see Section 11.4.
End of study
As for this study , important data may be collected after last subject last visit (LSLV), the end 
of the study  as a whole will be the date when the clean database is available.
Primary completion
The primary  completion event for this study  is LSLV.
6. Study population
6.1 Inclusion criteria
Subjects must fulfill all of the following criteria before being included in the treatment period:
1. Written informed consent obtained, dated and signed prior to an y screening 
procedures .
2.Health ymale or female subject –as determined by  the investigator or medically  
qualified designee base d on medical evaluations, including medical history , phy sical 
examination, laboratory  tests and cardiac monitoring .
3.Age: 18 to 45 y ears at the first screening visit.
4.Women of childbearing potential and men must agree to use highl y effective
contraception f rom signing of the informed consent form until at least 3 months after 
dosing. The investigator or a designated associate is requested to advise the subject
how to achieve highl y effective contraception. Highl y effective (failure rate of less 
than 1% per year) contraception methods include: c ombined (estrogen and 
progesterone containing: oral, intravaginal, transdermal) and progesterone -only (oral, 
injectable, implantable) hormonal contraception ; intrauterine device (IUD); 
intrauterine hormone -releasing system (IUS); bilateral tubal occlusion; or 
vasectomized partner (provided that partner is the sole sexual partner and has received 
medical assessment of the surgical success ). Periodic abstinence (e.g. calendar, 
ovulation, sy mptothermal, or postovulation methods) and withdrawal are not 
acceptable methods of contraception. I n addition, the use of condoms for subjects or 
their partners is required unless the woman is postmenopausal or permanently  
sterilized (hy sterectom y, bilateral oophorectom y).
Male subj ects must abstain from fathering a child.
5.Women must have a negative pregnancy  test (in blood or urine) within 7 days prior to 
the dose of stud y drug or be surgicall y or biologically sterile or postmenopausal.
Postmenopausal women are defined as:
Age ≤45 y ears with 6 months of spontaneous amenorrhea and follicle stimulating 
hormone level within postmenopausal range (>40 mI  U/mL) or
Permanently  sterilized women (hy sterectomy , bilateral oophorectomy ).
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 21of 63
6.Body mass index (BMI) of 18.0 -34.0 kg/m2, with body  weight 50kg
7.Subject must be willing to comply  with dietary ,fluid , and activity restriction sduring 
the treatment period (including abstaining from alcohol use) (see Sections 9.2.7.1 and
9.2.7.2 ).
8.Subject must have venous access sufficient to allow blood sampling as required by  the 
protocol .
9.Subject must be willing to undergo multiple blood draws as required b y the protocol .
10.Ability  to understand and follow study -related instructions .
11.Creatinine clearance ≥ 90 mL /min using the Modification of Diet in Renal Disease 
(MDRD formula ; see Section 16.4).
12.Adequate end organ and bone marrow function as defined b y:
Total bilirubin in the normal range
International normalized ratio (INR) lower or equal to 1.5 xupper limit of normal 
(≤1.5 ULN)
Alkaline phosphatase (AP) ≤1.5 UL N, Alanine am inotransferase (ALT)
≤1.5 ULN, aspartate aminotransferase (AST) ≤1.5 ULN
Neutrophils ≥ 1500/ μL, platelets ≥ 100,000/μL
13.Vital signs within the following ranges:
Systolic blood pressure ( BP) ≥90 mmHg and ≤15 0 mmHg
Diastolic BP ≥50 mmHg and ≤90 mmHg
Pulse rate 45 to 100 bpm
6.2 Exclusion criteria
Subjects are to be excluded from the stud y if they display an y of the following criteria :
Medical and surgical history
1.Existing relevant diseases of vital organs (e.g. liver diseases, heart diseases), central 
nervous s ystem (for example seizures) or other organs (e.g. diabetes mellitus).
2.Incompletel y cured pre -existing diseases for which it can be assumed that the 
absorption, distribution, metabolism, elimination and effects of the stud y drugs will 
not be normal.
3.Febrile illness within 1 week before the first study  drug administration.
4. A positive Hepatitis B surface antigen (HBsAg), Hepatitis C or human 
immunodeficiency  virus (HIV)test result .
5.A medical history  of risk factors for Torsades de pointes (e.g. famil y history  of Long 
QT Sy ndrome) or other arrhy thmias.
6. Known severe allergies, allergies requiring therapy  with corticosteroids, non -allergic 
drug reactions, or (multiple) drug allergies (excluding untreated as ymptomatic 
seasonal allergies such as non- severe h ay fever during the time of study  conduct).
7.Known history  of hy persensitivity  (or known allergic reaction) to copanlisib,
metformin, related compounds, or an y components of the formulation .
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 22of 63
8.Relevant renal disorders like recurrent glomerulonephritis, renal injury , and renal 
insufficiency .  However, a history  of a single episode of uncomplicated nephrolithiasis 
will not prevent participation.
9.Relevant respiratory insufficiency  /disorder (lung conditions that cause difficulty  
breathing).
10. Subjects with sleep apnoea s yndrome (frequent interruption of breathing during sleep).
11.Subjects with active pathological bleeding, with evidence or history  of bleeding 
diathesis.
12. Previous or concurrent cancer except for curatively treated cervical cancer in situ and 
curativel y treated non- melanoma skin cancer .
13.Subjects with any  type of psy chiatric disorder, especiall y any mood disorders 
including medical history with suicidal ideation and/or suicide attempts, which may 
disable the subject to consent.
Medication, drug use and sp ecial behavioral patterns
14.Subjects with known drug abuse within 1 month prior to dosing or evidence of such 
abuse as indicated b y the laboratory assay s conducted during the screening or baseline 
evaluations .
15.Alcohol consumption above the equivalent of 20 g alcohol average per day.
16.Donation or loss of 400 mL  or more of blood within 4 weeks prior to dosing .
17.Administration of strong CYP3A4 inhibitors or inducers within 2 weeks prior to 
dosing (see Appendix 16.3).
18.Use of immunosuppressive drugs .
19. Administration of medications that prolong the QT interval within 2 weeks prior to 
dosing (A list of agents that prolong the QT interval can be found at 
http://www.torsades.org/medical -pros/drug -lists/printable -drug-list.cfm. However, 
this list may  not be comprehensive) .
20.Use of an y prescription drug or over -the-counter (OTC) medication within 2 weeks or 
5-half-lives of the prescription medication prior to dos ing with copanlisib (whichever 
is longer), except for acetaminophen or ibuprofen within 7 day s before dosing .
21. Use of supplements or herbal remedies within 2 weeks prior to dosing with the 
exception of vitamins .
22.Use of investigational drugs (i.e. participat ion in any  clinical investigation) within 
30days prior to dosing or longer if required by  local regulation, or within 10 -half-
lives of the investigational agent taken (whichever is longer).
23. Intake of foods or beverages containing grapefruit, pomelo or Sev ille oranges within
1week before the study  drug administration. The juices and products containing these 
fruits must also be avoided .
24. Regular use of therapeutic or recreational drugs, e.g. carnitin products, anabolics, high 
dose vitamins .
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 23of 63
Other exclusion criteria
25.Inability  to understand the protocol requirements, instructions and study  related 
restrictions, the nature, scope, and possible consequences of the study .
26.Unlikelihood to comply  with the protocol requirements, instructions and study  related 
restrictions; e.g. uncooperative attitude, inability  to return for follow -up visits, and 
improbability  of completing the study .
27.Subject is the I nvestigator or any  Sub-Investigator, research assistant, pharmacist, 
study  coordinator, other staff or relative there of directly  involved in the conduct of the 
study .
28.Subject is in custody  by order of an authorit y or a court of law .
29.Previous assignment to treatment during this study .
6.3 Justification of selection criteria
The selection criteria are chosen to ensure that subjects with specific risks for administration 
of the study  drugs and/ or subjects with conditions which may  have an impact on the aims of 
the study  are excluded.
Justification of gender selection: Male and female subjects will be included providing they 
meet all the criteria for inclusion and do not fulfill any  of those for exclusion. No sex -specific 
effects of treatment are anticipated.
6.4 Withdraw al of subjects from study
6.4.1 Withdrawal
Withdrawal criteria
Subjects must be withdrawn from the stud y if an y of the following occurs:
At their own request or at the request of their legally  acceptable representative. At 
any time during the study and without giving reasons, a subject may  decline to 
participate further.  The subject will not suffer an y disadvantage as a result.
Subjects may be withdrawn from the stud y if an y of the following occurs:
If, in the investigator ’s opinion, continuation of the study  would be harmful to the 
subject ’s well -being
At the specific request of the sponsor and in liaison with the investigator (e.g. 
obvious non -compliance, safet y concerns).
Violation of in -/exclusion criteria: if the subject develops conditions which would 
have prevented his/her entry  into the study  according to the in-/exclusion criteria, 
he/she must be withdrawn i mmediately  if safet y is concerned; in other cases, the 
investigator will decide, after consultation with the sponsor, whether there is a 
conflict with the study  objectives.
Depending on the time point of withdrawal, a withdrawn subject is referred to as ei ther 
“screening failure” or “dropout” as specified below:
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 24of 63
Screening failure
A subject who, for an y reason (e.g. failure to satisfy the selection criteria), terminates the 
study  before the time point used for the definition of “dropout” (see below) is regar ded a 
“screening failure”.  
Re-starting the defined set of screening procedures to enable the “screening failure” subject’s 
participation at a later time point is not allowed – with the following exceptions:
The subject had successfully  passed the screeni ng procedures, but could not start 
subsequent treatment on schedule.
Initial screening occurred too earl y to complete the required washout period after 
prior therap y.
The in -/exclusion criteria preventing the subject’s initial attempt to participate 
have b een changed (via protocol amendment).
Thus, participation of an initial “screening failure” subject at a later time point even if he/she 
meets all selection criteria upon re -screening is not acceptable.
In an y case, the investigator has to ensure that the repeated screening procedures do not 
expose the subject to an unjustifiable health risk.  Also, for re -screening, the subject has to 
re-sign the informed consent form, even if it was not changed after the subject’s previous 
screening.
Dropout
A subject who discontinues study  participation prematurely  for any  reason is defined as a 
“dropout” if the subject has alread y been administered at least one dose of study  medication .
General procedures
In all cases, the reason for withdrawal must be recorded in the case report form (CRF )and in 
the subject ’s medical records.
The subject may  object to the generation and processing of post -withdrawal data as specified 
in Section 13.4.
Any subject removed from the trial will remain under medical supervision until discharge or 
transfer is medically  acceptable. If the subject has received study  drug ,an EOT visit is to be 
performed.
Details for the premature termin ation of the study  as a whole (or components thereof) are 
provided in Section 12(Premature termination of the study ).
6.4.2 Replacement
Subjects who drop out or do not receive all doses of study  drugs will be replaced to obtain a 
minimum of 12 subjects valid for PK of metformin.
6.5 Subject identification
At the beginning of screening, every  subject is given a subject number (9 -digit number 
consisting of: Digits 1 to 5 = Unique center number, Digits 6 to 9 = Current subject number )
within the center.
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 25of 63
7. Treatments
7.1 Treatments to be administered
All subjects wil l receive 2 oral doses of metformin , 1dose (1000 mg )on Day 1 and 1dose
(1000 mg) on Day 8, and a single i.v. dose of copanlisib (60mg, 1 h infusion) on Day 8.
The treatments to be administered during the study are display ed in Table 7–1.
Table 7–1: Treatments to be administered
Treatment Route of 
administrationDose, formulation Frequency and time of 
administrationNumber of 
subjects treated
Metformin Oral 1000 mg, tablet Single dose on Day 1 12-15
Metformin Oral 1000 mg, tablet Single dose on Day 8 12-15
Copanlisib i.v. 60 mg, 1 h infusion Single dose on Day 8 12-15
7.2 Identity of study treatment
Copanlisib
Copanlisib is supplied as a ly ophilized preparation in a 6 mL  glass injection vial. The total 
amount of BAY 80 -6946 per vial is 60 mg. The solution for i.v. infusion is obtained after 
reconstitution of the lyophilisate with 0.9% sodium chloride solution.
Please refer to the Pharmacy  Manual for detailed instructions for the reconstitution of the 
lyophilisate and for further dilution of the reconstituted solution.
Please refer to IB for copanlisib for more details regarding drug properties and formulation.
Metformin
Metformin will be sourced centrall y or locally depending on the local law and requirements.  
The source of the metformin will be documented in the sponsor’s study  file.  For full details 
on metformin, please refer to the current prescribing info rmation / SmPC.
Study drug supply
All centrall y supplied study  drugs will be labeled according to the requirements of local law
and legislation.  Label text will be approved according to the sponsor’s agreed procedures, 
and a cop y of the labels will be mad e available to the study  site upon request.
For all centrall y supplied study  drugs, a s ystem of numbering in accordance with all 
requirements of Good Manufacturing Practice ( GMP )will be used, ensuring that each dose of 
study  drug can be traced back to the respective bulk batch of the ingredients.  L ists linking all 
numbering levels will be maintained by  the sponsor’s clinical supplies Quality  Assurance
(QA)group. 
Acomplete rec ord of batch numbers and expiry dates of all study  treatment as well as the 
labels will be maintained in the sponsor’s study  file.
7.3 Treatment assignment
All subjects will receive the same treatments in this open- label, non -randomized study .
Please refer to Section 6.5for subject identification.
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 26of 63
7.4 Dosage andadministration
All subjects will receive 2 doses of metformin, 1dose (1000 mgtablet) o n Day 1 and 1dose
(1000 mgtablet) on Day 8, and a single dose of copanlisib (60 mg infusion ) on Day 8.
Copanlisib is administered in a normal saline solution i.v.over 1 hour; refer to Section 7.2for 
further details.
Regarding the selection of copanlisib and metformin dose in the study , refer to Section 3.3.
Regarding doses, route / mode of administration, and formulations, refer to Section 7.1.
Subjects will need to fast overnight before metformin admi nistration on Day s1 and 8. They  
will continue fasting until 3 hours after metformin dosing and will then be given a low-
carboh ydrate meal (eggs, cheese and/or plain yogurt, vegetables, meat).   On Day 8, metformin 
will be given just before the start of the copanlisib infusion.
7.5 Blinding
This study  will be performed in a non -blinded design, as the primary  objective of this trial is 
the investigation of PK and because the PKresults will neither be affecte d by the subjects nor 
by the investigator(s).
7.6 Drug logistics and accountability
All study  drugs will be stored at the investigational site in accordance with GCP and GMP 
requirements and the instructions given b y the clinical supplies department of the spo nsor (or 
its affiliate/ contract research organization [ CRO ]), and will be inaccessible to unauthorized 
personnel.  Special storage conditions and a complete record of batch numbers and expiry  
dates can be found in the sponsor’s study  file; the site -relevan t elements of this information 
will be available in the investigator site file.  On the day of receipt, the responsible site 
personnel will confirm receipt of study  drug in writing .  The personnel will use the study  drug 
only within the framework of this c linical study  and in accordance with this protocol.  
Receipt, distribution, return and destruction (if an y) of the stud y drug must be properl y 
documented according to the sponsor’s agreed and specified procedures.
Written instructions on medication destruc tion will be made available to affected parties as 
applicable.
If performing drug accountability  implies a potential risk of contamination, a safet y process/ 
guidance for handling returned drug will be provided.
7.7 Treatment compliance
The administration of t he study  drugs will be done by  a member of the investigator’s team. 
This person will ascertain and document that the subject receives the treatment as planned.
Further information about the subject’s treatment compliance can be derived from drug 
concentra tion measurements in plasma.
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 27of 63
8. Non- study therapy
8.1 Prior and concomitant therapy
All prior medication used within 4weeks before the screening visit will be documented 
(medication history ).
Refer to Section 6.2for medication representing exclusion criteria.
Copanlisib is primarily  metabolized by  CYP3A4. Concomitant use of CYP3A4 inhibitors 
and inducers (see list in Appendix 16.3) is therefore not permitted from 2 weeks before the 
administration of study  drug until 24 hours after dosing on Day 8 (after the last PK blood 
sample has been collected) in this study .
Use of medication for concomitant therap y is not planned. Especially  the use of medication 
that may  have an impact on the study  objectives is not permitted. This comprises an y 
medication (including herbal remedies or food supple ments), which could affect the PK 
and/or PD of the stud y drug s. The subjects will be instructed to report any  concomitant 
medication used to the investigator. All concomitant medication will be documented.  In 
particular, this documentation will be expan ded by the exact time of day  for any  concomitant 
medication used during the in -house phase.
8.2 Post- study therapy
After the end of this study, further treatment is not necessary  since onl y healthy  subjects will 
be included in the study .
9. Procedures and variabl es
9.1 Tabular schedule of evaluations
See flow chart sin Section 16.1.
Regarding protocol deviations, the processes and responsibilities defined by the sponsor will 
befollowed. Respective details (e.g. identification and classification of protocol deviations) 
are described separatel y.
9.2 Visit description
The following measures/actions will be performed at the time points given in the flow charts 
in Section 16.1. Details on the parameters measured for safet y laboratory  examinations are 
provided in Section 16.2.
If not stated otherwise, the measures/actions listed in the following Sections 9.2.1 to 9.2.7 will 
be performed b y or under the supervision of an investigator.
9.2.1 Screening
Due to the fact that not all subjects may  fulfill the inclusion/exclusion criteria, a higher 
number of subjects than needed to be valid for the evaluation of the stud y will be asked to 
participate in the screening examinations.
A subject information session will be held. If the (first) screening procedures alread y start on 
the same day (same date) as the subject signs the informed consent form, the time o f the 
subject’s signature must be recorded in the source documents .
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 28of 63
Note: No screening procedures may be performed unless written informed consent has 
been obtained.
After obtaining the subject’s signature on the consent form, the below listed screening 
procedures will be performed and the respective results will be assessed within approximately  
28daysprior to the first study  drug administration:
Allocation of subject number (see Section 6.5)
Demographic data
Weight, height, BMI
Questioning for special behavior (e.g. smoking history , alcohol consumption, 
dietary  habits incl. consumption of food supplements)
Medical and surgical history
Participation in previous clinical studies
Current and p revious medication ( relevant medication history  up to 28daysprior
to first study  drug administration) and concomitant medication
Physical examination (general)
Vital signs : blood pressure, pulse rateand temperature, after resting for at least 
10minin supine position
12-lead ECG after resting for at least 10 min in a supine position
Adverse events before start of treatment (e.g. signs / sy mptoms of the subject; 
results of phy sical examination)
Blood and urine samples for th e safet y laboratory  examinations described in 
Section 16.2
Glycated hemoglobin ( HbA1c )
Virology  (described in Section 16.2)
Urine drug screen (see Section 16.2 for details)
Alcohol breath test
Pregnancy  test (blood or urine), if applicable.
Based on the information obtained from the above assessments, i.e. once all results (including 
laboratory  data) are available, the subject’s eligibility  will be decided upon:
Eligibility  check
No subject may  be included unless adhere nce to all selection criteria as given in Sections 6.1
and 6.2is established.
In case of abnormal results caused b y intercurrent diseases, short -term treatable conditions or 
other temporary  health disorders (e.g. acute infection, iron deficiency , blood pressure outside 
defined range), the investigator may  decide to repeat the respective screening parameter(s). 
As a rule, up to 2 repetitions are acceptable.  In any  case, the investigator must ensure that the 
repeated screening procedures do not expose the subject to an unjustifiable health risk.
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 29of 63
9.2.2 Pre-dose ( Study Day -1)
The su bjects will arrive at the study  site in the evening of Study  Day -1, the day  before study
drug administration. The following measures/actions will be carried out: 
Open questioning for and documentation of AEs and update on previous 
medication
Alcohol bre ath test
Physical examination
Vital signs: blood pressure (to be measured in the same arm throughout the study ), 
pulse rate and temperature, after resting for at least 10 min in supine position
Start overnight fasting for at least 10 hours before administration of the study  
medication (drinking of water allowed)
Pregnancy  test (blood or urine), if applicable, if screening pregnancy  test was not 
within the previous 7 days.
9.2.3 Randomization
Randomization is not applicable.
9.2.4 Treatment Period
If 2 or more measures/ actions coincide at one time point, they  should be performed according 
to the preferred sequence: ECG –blood pressure/ pulse rate – blood sampling for PK at 
defined time point(s) – blood sampling for safety – urine sample . In the e vent that results of 
the plasma glucose testing are not available, capillary  glucose measurements may  be used to 
manage the safet y of the subject. Any of the standardized meals will be served after the 
measures/actions for a given time point are completed.
9.2.4.1 Study Day 1
The following measures/actions will be performed before dosing :
Fasting to be continued (drinking of water allowed)
Open questioning for and documentation of AEs and update on concomitant 
medication
12-lead ECG after resting for at least 10 mi n in a supine position
Vital signs : blood pressure, pulse rate and temperature, after resting for at least
10minin supine position
Blood and urine samples for the safety laboratory  examinations described in 
Section 16.2. These may be done on Day -1 if necessary , to ensure that the results 
are available prior to dosing.
Fasting glucose pre- dose
Final check of inclusion and exclusion criteria
Blood sample for metformin PK (baseline sample)
Blood samples for PD evaluation (plasma lactate, glucose, insulin and c -peptide;
baseline samples)
Urine sample for metformin PK (baseline sample)
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 30of 63
Subjects will receive study  treatment in the morning as follows:
Single dose of metformin (1000 mg tablet)
The following measures/actions will be performed after dosing at the time points given in the 
schedule in Table 16–2:
Subjects will be asked to drink 8 oz (~237 mL ) of water every  2 hours during 
waking hours to maintain urine flow and pH
Fasting to be continued until 3 hours after metformin dosing
Open questioning for and documentation of AEs and update on conco mitant 
medication
12-lead ECG after resting for at least 10 min in a supine position
Vital signs : blood pressure, pulse rate and temperature, after resting for at least 
10min in supine position
Blood samples for metformin PK
Blood samples for PD evaluation (plasma lactate, glucose, insulin and c -peptide)
Urine sample collections for metformin PK
Blood and urine samples for the safety laboratory  examinations described in 
Section 16.2.
After completion of the Day 1measures/ actions (relative time Day 1,up to 24 hours) , the 
subjects will be discharged from the stud y site in the morning of Day 2, provided there are no 
medical objections. They  will return in the evening of Day 7.
9.2.4.2 Study Day 7
The subjects will arrive at the investigational site in the evening before study  drug 
administration .The following measures/actions will be carried out: 
Open questioning for and documentation of AEs and update on concomitant 
medication
Alcohol breath test
Physical examination
Vital signs : blood pressure, pulse rate and temperature, after resting for at least 
10minin supine position
Start overnight fasting for at least 10 hours before administration of t he study  
medication (drinking of water allowed)
9.2.4.3 Study Day 8
The following measures/actions will be performed before dosing :
Fasting to be continued (drinking of water allowed)
Open questioning for and documentation of AEs and update on concomitant 
medication
12-lead ECG after resting for at least 10 min in a supine position
Vital signs : blood pressure, pulse rate and temperature, after resting for at least 
10minin supine position .
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 31of 63
Blood pressure will be measured prior to the administration of the copanlisib, until 
2 consecutive values are <150/90 mmHg with at least a 15 min interval between 
measurements . Up to 4 measurements may  be taken before drug administration.
If the blood pressure is not <150/90 mmHg, copanlisib cannot be administered.
Blood and urine samples for the safety laboratory  examinations described in 
Section 16.2. These may be done on Day 7 if necessary , to ensure that t he results 
are available prior to dosing.
Fasting plasma glucose. Copanlisib infusion can only  be administered if fasting 
glucose is ≤125mg/dL
Blood sample for metformin PK (baseline sample)
Blood sample for copanlisib PK (baseline sample)
Blood sample s for PD evaluation ( plasma lactate, glucose, insulin and c -peptide;
baseline samples)
Urine sample for metformin PK (baseline sample)
Subjects will receive study  treatment in the morning as follows:
Single dose of metformin (1000 mg tablet)
Intravenous infus ion of copanlisib (60 mg, 1hour infusion ), immediately (within 
5-10 mins) after the metformin dose
The following measures/actions will be performed after dosing at the time points given in the 
schedule in Table 16–2:
Subjects will be asked to drink 8 oz (~237 mL ) of water every  2 hours during 
waking hours to maintain urine flow and pH
Fasting to be continued until 3 hours after metformin dosing
Open qu estioning for and documentation of AEs and update on concomitant 
medication
12-lead ECG after resting for at least 10 min in a supine position
Vital signs : blood pressure, pulse rate and temperature, after resting for at least 
10min in supine position
Bloodsample sfor metformin PK
Blood sample sfor copanlisib PK
Blood sample sfor PD evaluation (plasma lactate, glucose, insulin and c -peptide)
Urine sample collections for metformin PK
Blood and urine samples for the safety laboratory  examinations described in 
Section 16.2.
After completion of the Day 8 measures/actions (relative time Day  8,up to 24 hours) , the 
subjects will be discharged from the stu dy site on the morning of Day 9, provided there are no 
medical objections.
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 32of 63
9.2.5 End of treatment visit
The following measures/actions will be performed at the EOT visit ,7 to 14 days after 
administration of copanlisib:
Adverse events
Current and previous medication (medication history )
Physical examination
Vital signs : blood pressure, pulse rate , temperature
ECG
Plasma glucose
HbA1c
Blood and urine samples for the safety laboratory  examinations described in 
Section 16.2
9.2.6 Follow- up
A follow -up assessment w ill be conducted b y telephone , 30to 35 days after last 
administration of the study  medication . The following measures/actions will be performed :
Adverse events
Current and previous medication (medication history)
If clinicall y indicated ( e.g. if the subject has an y AEs), then afollow -up visit should be 
conducted in -house, and the following measures/actions performed:
Adverse events
Current and pre vious medication (medication history )
Physical examination
Vital signs : blood pressure, pulse rate , temperature
ECG
Blood sample for safet y (clinical chemistry, hematology, coagulation)
Urine sample for safety  (dipstick ± sediment)
9.2.7 Special conditions durin g the study
9.2.7.1 Restrictions
Restrictions to be observed by  the subjects are display edin Table 9–1.
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 33of 63
Table 9–1: Restrictions during the study
Restriction Period of restriction
Concomitant medications Please refer to Section 8.1
Smoking Not allowed during the in-house phases of the study
Caffeine Not permitted on PK sampling days
Alcohol Not permitted from 48hours prior to each study  drug 
administration and during the in-house phases
Xanthine -containing beverages and food Not permitted from 24hours prior to each drug 
administration and during the in -house phases
Foods or beverages containing grapefruit, 
pomelo or Seville oranges. Juices and 
products containing these fruits must also be 
avoided.Not permitted within 1 week before the study drug 
administration until EOT
Physical activity Strenuous exercise is not allowed from 72 hours 
before admission to the study site until 96 hours after 
study drug administration
Donation of whole blood/components of blood Donation of 400 mL or more of blood within 4 weeks 
prior to dosing and through EOT visit
9.2.7.2 Food and drink
Subjects must fast overnight before metformin administration on Day s 1 and 8 (water is 
permitted) . They must continue fasting until 3 hours after metformin dosing and will then be 
given a low- carboh ydrate meal (eggs, cheese and/or plain y ogurt, vegetables, meat).
Food and drink will be served after the stud y-related measures/actions of that time point have 
been performed.
9.2.7.3 Accomodation
Visit: Approximate duration: Overnight stays:
Screeni ng 2hours
Day 1 36-48 hours 2
Day 8 36-48 hours 2
EOT 1 hour
Follow-up 1 hour (if conducted in- house )
9.3 Population characteristics
9.3.1 Demographic
For demographic assessment, the following parameters will be recorded:
Year of birth/age, sex, race, bod y weight , height , and BMI .
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 34of 63
9.3.2 Medical history
Medical history  findings (i.e. previous diagnoses, diseases or surgeries) meeting all criteria 
listed below will be collected as available to the investigator:
Start before signing of the informed consent 
Considered relevant for the subject’s study  eligibility .
Detailed instructions on the differentiation between (i) medical history  and (ii) AEs can be 
found in Section 9.6.1.1 .
9.3.3 Other baseline characteristics
Information on smoking, diet, and alcohol consumption will be collected .
9.4 Efficacy
Not applicable.
9.5 Pharmacokinetics / pharmacodynamics
9.5.1 Pharmacokinetics
9.5.1.1 Drug measurements
Blood samples for PKanaly sisof metformin and copanlisib in plasma will be collected at the 
time points given in the schedule of assessments in Section 16.1 ( Table 16–2) and in Table 9–
2below.
Urine forPKanaly sis of metformin will be collected at the time points given in the schedule 
of assessments in Section 16.1 ( Table 16–2) and in Table 9–3below.
Regarding handling of the samples collected, refer to Section 16.2.The PK anal yseswill be 
performed using validated anal ytical methods. Quality  control (QC) and calibration samples 
will be anal yzed concurrently  with study  samples. The results of calibration samples and QC 
samples will be reported in the Bioanal ytical Report which will be included in the Clinical 
Study  Report for this study . Concentrations are calculated from the chromatographic raw data 
in accordance with current Bay er guidelines.
The PKcalculations will be based on the actual sampling and dosing times. Therefore, it is of 
importance to have this data thoroughly  documented in the CRF. Deviations from the 
specified time points will be documented and take n into account when calculating the PK 
parameters.
Whenever possible, all efforts should be made to adhere to the sampling schedule in the Table 
16–2. However, based on practical considerations, the following time range is provided : 
pre-dose samples should be collected within 30 min before drug administration ;for planned 
time points ≤6 h post -dose (except for pre -dose samples), PK samples should be col lected 
within ±15 min of the planned time; and for planned time points >6 h post-dose, PK samples 
should be collected within ±30 min.
Cumulated substantial deviations of sampling times and/or consecutive, missing PK samples 
may lead to an insufficient desc ription of the concentration -time profile(s) of anal yte(s), and 
thus affect the quality  of the PK evaluation of the respective subject(s). In this case these 
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 35of 63
deviations should be classified as “important” and may  lead as declared “validity  findings” to 
the exclusion of the respective subject(s) from the PK analy sis set.
Detailed information about the collection, processing, storage and shipment of the samples 
will be provided separately , e.g. sample handling sheets and/or laboratory  manual.
Table 9–2: PK sampling and dosing time points for metformin and copanlisib in 
plasma
Day Relative time 
after dose (h)1000 mg Metformin oral PK sampling 
for metforminPK sampling 
for copanlisib
1 0ax xa-
1 0.5 x -
1 1 x -
1 1.5 x -
1 2 x -
1 2.5 x -
1 3 x -
1 4 x -
1 6 x -
1 8 x -
1 10 x -
1 12 x -
1 16 x -
1 24 x -
Day Relative time 
after dose (h)60 mg copanlisib i.v.
1h infusion +
1000 mg metformin oralPK sampling 
for metforminPK sampling 
for copanlisib
8 0ax xaxa
8 0.5 x x
8 1 x x
8 1.5 x -
8 2 x x
8 2.5 x -
8 3 x -
8 4 x x
8 6 x x
8 8 x x
8 10 x -
8 12 x x
8 16 x -
8 24 x x
a = pre -dose before drug administration
-=no sample collection
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 36of 63
Table 9–3: Urine sample collection for metformin PK evaluation on Day s1 and 8
Study Day Time windows
1 0-2 h
2-4 h
4-8 h
8-12h
12-24h
8 0-2 h
2-4 h
4-8 h
8-12h
12-24h
9.5.1.2 Pharmacokinetic evaluation
Non compartmental analysis (NCA)
The PK parameters will be calculated according to the Sponsor’s current guidelines and the 
version of the PKsoftware WinNonlin used at the time of evaluation. Detailed information 
regarding the version will be given in the stud y report. Based on the concentration time data, 
the following PK parameters will be calculated :
Main parameters: Metformin :
Day 1 and Day 8 : Cmax, AUC (0-24) andAUC
Additional parameters Metformin :
Day 1 and Day 8 :
%A E,ur, AE,ur, %A E,ur(t1-t2), A E,ur(t1-t2) where t1 and t2 are the 
start and the stop times of the urine collection interval
tmax, VZ/F, CL/F, t 1/2, and CL R (calculated as 
CL R= A E,ur(0-24)/AUC(0 -24))
Copanlisib :
Day 8 : Cmax, tmax, C6h, C24h and AUC (0-24)
Optional analysis
Simulations of plasma concentration versus time profiles might be performed utilizing 
compartmental evaluation methods to estimate systemic exposure following administration of 
other dosing regimens. This will be reported under separate cover, if applicab le.
Pharmacokinetic data for copanlisib collected during the stud y ma y be analyzed using non -
linear mixed -effects models. Details of the model building process including model 
evaluation will be provided in a separate data analy sis plan.
9.5.2 Pharmaco dynamics
The c hange in PDmarkers will be anal yzed in plasma samples collected during metformin 
alone or in combination with copanlisib. The list of PDparameters and the rationale for 
measurement for both metformin and copanlisib is provided in Table 9–4. Pharmacod ynamic 
sampling time points are provided in Table 9–5.
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 37of 63
Table 9–4 : Pharmacodynamic assessment and rationale
Pharmacodynamic 
measurementsRationale
Plasma lactate levels on 
Days1 and 8Lactic acidosis is a rare, but serious and infrequent 
(0.03/1000 patient -years) complication of metformin therapy for 
diabetes mellitus, where plasma lactate levels exceed 5 mmol/L(5). 
Plasma lactate levels will be measured in this study as a PD variable
Glucose, insulin and c -peptide 
on Day s1 and 8These glucose metabolism markers will be used as PD markers 
mediated b y PI3K of copanlisib effects as shown below [PI3K 
signaling pathway in glucose metabolism]
GSK3 = Glycogen synthase kinase 3
IRs = insulin receptors
PD = pharmacodynamic
pAKT = phosphor ylated protein kinase B (phospho -AKT)
PI3K = phosphatidylinositol 3 -kinase
RTKs = receptor tyrosine kinases
Table 9–5: Pharmacodynamic sampling
Pharmacodynamic measurements Sampling time point
Plasma lactate levels on Day 1 and 8 0(pre-dose before drug administration), 30 min, 
and 1, 2, 4, 6, 8, 12 and 24 h
Glucose, insulin and c -peptide on Day 1 and 8 0 (pre- dose before drug administration) 30 min, 
and 1, 2, 4, 6, 8, 12 and 24 h
9.6 Safety
9.6.1 Adverse events
9.6.1.1 Definitions
Definition of adverse event (AE)
In a clinical stud y, an AE is any untoward medical occurrence (i.e. any unfavorable and 
unintended sign [including abnormal laboratory  findings], sy mptom or disease) in a patient or 
clinical investigation subject after providing written informed consent for participation in the 
study .  Therefore, an AE may  or may  not be temporally  or causally  associated with the use of 
a medicinal (investigational) product.

Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 38of 63
A surgical procedure that was planned prior to the start of the study  by any physician treating 
the subject should not be recorded as an AE (however, the condition for which the surgery  is 
required may  be an AE).
In the following differentiation between medical history  and AEs, the term “condition” may  
include abnormal e.g. phy sical examination findings, s ymptoms, diseases, laboratory , ECG .
Conditions that started before signing of informed consent and for which no 
symptoms or treatment are present until signing of informed consent are recorded 
as medical history (e.g. seasonal allergy  without acute complaints).
Conditions that started before signing of informed consent and for which 
symptoms or treatment are present after signing of informed consent, at unchanged 
intensity , are recorded as medical history (e.g. allergic pollinosis) .
Conditions that started or deteriorated after signing of informed consent will be 
documented as adverse events .  This includes intercurrent illnesses.
Definition of serious adverse event (SAE)
An SAE is classified as any  untoward medical occurrence that, at an y dose, meets an y of the 
following criteria (a –f):
a.Results in death
b.Is life -threatening
The term ‘life-threatening’ in the definition refers to an event in which the subject was 
at risk of death at the time of the event, it does not refer to an event which 
hypothetically  might have caused death if it were more severe.
c.Requires inpatient hospitalizatio n or prolongation of existing hospitalization
A hospitalization or prolongation of hospitalization will not be regarded as an SAE if 
at least one of the following exceptions is met:
-The admission results in a hospital stay  of less than 12 hours
-The admiss ion is pre -planned
(e.g. elective or scheduled surgery  arranged prior to the start of the study ; 
admission is part of the study  procedures as described in Section 9.2)
-The admission is not asso ciated with an AE 
(e.g. social hospitalization for purposes of respite care).
However, it should be noted that invasive treatment during an y hospitalization may 
fulfill the criterion of ‘medicall y important’ an d as such may  be reportable as an SAE 
dependent on clinical judgment.  In addition, where local regulatory  authorities 
specificall y require a more stringent definition, the local regulation takes precedence.
d.Results in persistent or significant disability  / incapacity
Disability means a substantial disruption of a person’s ability  to conduct normal life’s 
functions.
e.Is a congenital anomal y / birth defect
f.Is another serious or important medical event as judged b y the investigator
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 39of 63
9.6.1.2 Classifications for adverse event assessment
All AEs will be assessed and documented b y the investigator according to the categories 
detailed below.
9.6.1.2.1 Seriousness
For each AE, the seriousness must be determined according to the criteria given in 
Section 9.6.1.1 .
9.6.1.2.2 Intensity
The intensity  of an AE is classified according to the following categories:
-Mild (A ty pe of AE that is usually  transient and may require only  minimal treatment or 
therapeutic intervention. The event does not generally  interfere with usual activities of 
daily  living)
-Moderate (A t ype of AE that is usually  alleviated with additional specific therapeutic 
intervention. The event inte rferes with usual activities of daily  living, causing discomfort 
but poses no significant or permanent risk of harm to the research participant)
-Severe (A ty pe of AE that requires intensive therapeutic intervention. The event
interrupts usual activities o f daily  living, or significantly  affects clinical status. Theevent 
possesses a significant risk of harm to the research participant and hospitalization may  be 
required).
9.6.1.2.3 Causal relationship
The assessment of the causal relationship between an AE and the administration of treatment 
is a decision to be made by  the investigator, who is a qualified phy sician, based on all 
information available at the time of the completion of the CRF.
Causality  should be assessed separatel y for each study treatment as detaile d in the CRF.  If the 
investigator feels that the event cannot be firml y attributed to one of the study treatments 
(e.g. owing to a suspected underly ing interaction), the same assessment will be documented 
for each study treatment.
The assessment is based on the question whether there was a “reasonable causal relationship” 
to the study  treatment in question.
Possible answers are “y es” or “no” .
An assessment of “no” would include:
1.The existence of a high lylikely  alternative explanation, e.g. mechanical blee ding at 
surgical site.
or
2.Non-plausibility , e.g. the subject is struck by  an automobile when there is no 
indication that the drug caused disorientation that may  have caused the event; cancer 
developing a few day s after the first drug administration.
An ass essment of “y es” indicates that that the AE is reasonabl y associated with the use of the 
study  treatment.
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 40of 63
Important factors to be considered in assessing the relationship of the AE to study  treatment 
include:
- The temporal sequence from drug administration:  The event should occur after the drug 
is given.  The length of time from drug exposure to event should be evaluated in the 
clinical context of the event.
-Recovery  on drug discontinuation (de -challenge), recurrence on drug re- introduction 
(re-challenge): Subject’s response after de -challenge or re -challenge should be 
considered in view of the usual clinical course of the event in question.
-Underl ying, concomitant, intercurrent diseases:  
Each event should be evaluated in the context of the natural histor y and course of the 
disease being treated and any  other disease the subject may  have.
-Concomitant medication or treatment: 
The other drugs the subject is taking or the treatment the subject receives should be 
examined to determine whether an y of them migh t have cause dthe event in question.
-Known response pattern for this class of drug: Clinical/preclinical
-Exposure to phy sical and/or mental stresses: The exposure to stress might induce adverse 
changes in the recipient and provide a logical and better expl anation for the event
-The pharmacology  and PKof the study  treatment: 
The PKproperties (absorption, distribution, metabolism and excretion) of the study  
treatment, coupled with the individual subject’s pharmacod ynamics should be 
considered.
Causal relationship to protocol -required procedure(s)
The assessment of a possible causal relationship between the AE and protocol -required 
procedure(s) is based on the question whether there was a “reasonable causal relationship” to 
protocol -required procedure(s).
Possible answers are “y es” or “no” .
9.6.1.2.4 Action taken with study treatment 
Any action on study  treatment to resolve the AE is to be documented using the categories 
listed below.
The study  treatment action should be recorded separatel y for each stud y treatment as detailed 
in the CRF.
-Drug withdrawn
-Drug interrupted
-Not applicable
-Unknown
9.6.1.2.5 Other specific treatment(s) of adverse events
-None
-Remedial drug therap y
-Other
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 41of 63
9.6.1.2.6 Outcome
The outcome of the AE is to be documented as follows: 
-Recovered/resolved
- Recovering/resolving
-Recovered/resolved with sequelae
-Not recovered/not resolved
-Fatal
-Unknown
9.6.1.3 Assessments and documentation of adverse events
The investigator has to record on the respective CRF pages all AEs occurring in the period 
between the signing of the informed consent and the end of the follow -up phase (30 to 
35days after last dose of study  medication) . AEs observed, mentioned upon open 
questioning b y a member of the investigator’s team, or spontaneously reported by the subject 
will be documented . After the end of the follow -up phase , there is no requirement to activel y 
collect AEs including deaths. In case of ongoing AEs after the last follow -up visit –
especiall y when related to treatment with the study medication –the respective AE will be 
followed until resolution, if possible.
The ty pe of information that should be assessed and recorded by  the investigator for each AE 
is listed in Section 9.6.1.2 . The date and time of onset will be recorded.
“Death” should not be recorded as an AE on the AE page.  Instead, “death” is the outcome of 
underly ing AE(s).
For all SAEs the sponsor has to carry  out a separate assessment for expectedness, se riousness 
and causal relationship to study  drug.
9.6.1.4 Reporting of serious adverse events
The definition of SAEs is given in Section 9.6.1.1 .  Each SAE must be followed up until 
resolution or stabilization by  submission of updated reports to the designated recipient.
Investigator’s notification of the sponsor
All investigators will be thoroughly instructed and trained on all relevant aspects of the 
investigator’s reporting obligations for SAEs.  This information, including all relevant contact 
details, is summarized in the investigator site file.  This information will be updated as 
needed.
The investigator must report immediately  (within 24 hours of the investigator’s awareness) all 
SAEs occurring during the observation period defined in Section 9.6.1.3 to the recipient 
detailed in the instruct ions for SAE reporting included in the Investigator File.  For this, an 
AE page in the CRF must be completed for each SAE.
SAEs occurring after the protocol -defined observation period will be processed by  the 
sponsor according to all applicable regulations .
In each case of fatal or life -threatening reaction, the investigator must seek relevant follow-up 
information and must complete a follow -up report to be faxed to the sponsor as soon as 
possible but not later than 8 calendar day s after the initial report is sent.
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 42of 63
For all SAEs, the investigator is required to document in full, the course of the SAE and any  
therap y given, including any  relevant findings / records in the report.
Notification of the IECs / IRBs
Notification of the independent ethics committee s (IECs)/ institutional review board s (IRBs)
about all relevant events (e.g. SAEs, suspected unexpected serious adverse reactions 
[SUSARs] ) will be performed by the sponsor and/or by the investigator according to all 
applicable regulations.
Notification of the authorities
The processing and reporting of all relevant events (e.g. SAEs, SUSARs ) to the authorities 
will be done by  the sponsor according to all applicable regulations.
Sponsor’s notification of the investigational site
The sponsor will inform all investigational sites about reported relevant events (e.g. SUSARs)
according to all applicable regulations.
9.6.1.5 Expected adverse events
The expectedness of AEs will be determined b y the sponsor according to the applicable 
reference document and according to al l local regulations.
Adverse events possibly related to the testdrug, copanlisib
For this study , the applicable reference document is the most current version of the IB.
Overview listings of frequent events that have occurred so far in the clinical develo pment are 
shown in the current IB.  If relevant new safet y information is identified, the information will 
be integrated into an update of the IB and distributed to all participating sites.
Adverse events possibly related to the interaction drug, metformin
For this study , the applicable reference document is the summary  of product characteristics of 
metformin(6).
Very  common side effects (1/10) :gastrointestinal disorders such as nausea, vomiting, 
diarrhoea, abdominal pain and loss of appetite. These undesirable effects occur most 
frequentl y during initiation of therap y and resolve spontaneously  in most cases.
Common side effects (>1/100 and <1/10) : taste disturbance
Very  rare side effects (<1/10,000 ): skin reactions such as erythema, pruritus, and urticaria ; 
lactic acidosis.
Frequency  not known: i solated reports of liver function tests abnormalities or hepatitis 
resolving upon metformin hy drochlo ride discontinuation .
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 43of 63
Expected conduct- related AEs
The frequent blood sampling (b y single vein puncture and / or indwelling cannula) may be 
accompanied b y mild pain, hematoma and in rare cases inflammation of the vessel wall or 
injury  of a nerve. Awareness should be raised to the possibility  of a vasovagal attack or 
syncope (marked by  pallor, nausea, sweating, brady cardia, decrease in arterial blood pressure 
which, when below critical level, results in dizziness and /or loss of consciousness) duri ng the 
sampling procedure.
The use of adhesive electrodes (ECG leads) and / or adhesive dressings may  be accompanied 
by mild and transient reddening and / or itching of the skin.
9.6.1.6 Adverse events of special safety interest
Copanlisib is an investigational dr ug and current knowledge of the AEs associated with this 
compound is limited.  As with any  new chemical entity , there is alway s potential for 
unexpected AEs, including h ypersensitivity  reactions. 
Based on data from prior and ongoing clinical studies with copanlisib, as soon as there is 
reasonable suspicion of the following AE, the investigator should immediately  notify  the 
sponsor as outlined in Section 9.6.1.4 , regardless of whether the investigator assessed the AE 
as serious or non -serious:
Non-infectious pneumonitis.
9.6.1.7 Recommendations for the management of specific adverse events
9.6.1.7.1 Management of glucose increases that can occur with study treatment
Asymptomatic transient glucose increases
Mild to moderate as ymptomatic increases of blood glucose may  occur after study  drug 
infusion, with larger increases potentiall y occurring post -prandial. Transient asy mptomatic 
glucose increases that are ≤250 mg/dL do generally  not require treatment with glucose -
lowering medication. Subjects with post -dose blood glucose >250 mg/dL should have 
repeated laboratory  glucose measurements to verify  if the values are persistent or decreasing. 
If the repeated glucose value s are decreasing, glucose levels may  be followed without 
glucose -lowering medication if the subject is asymptomatic and if hy dration status is normal 
as clinically  assessed.
In the event that results of the plasma glucose testing are not available, capilla ry glucose 
measurements may  be used to manage the safet y of the subject.
Symptomatic or persisting glucose increases
Hydration status: If the subject has s ymptomatic glucose increase of any  grade, h ydration 
status should be clinically assessed. If the cli nical assessment is consistent with dehy dration, 
fluids should be given as clinically  appropriate (orally  or i.v.).
Glucose -lowering medication: Subjects with post -dose blood glucose >250 mg/dL should 
have repeated laboratory  glucose measurements to verify if values are persistent or 
decreasing. If a blood glucose level of >250 mg/dL persists upon confirmation by  repeated 
laboratory  anal ysis, and/or the subject is sy mptomatic, and/or the hy dration status indicates 
the need for h ydration, glucose -lowering m edication should be administered: Rapid or short -
acting (regular) insulin may  be given for blood glucose levels that are persisting at 
>250 mg/dL, or if the subject is symptomatic during the infusion day . “Sliding scale” short -
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 44of 63
acting or (regular) insulin coverage of blood glucose levels that are persisting at >250 mg/dL 
is recommended, with oral or i.v. hydration as clinically  appropriate. Only  the use of short -
acting (rapid -acting) insulin is recommended for treatment of glucose increases after the 
singl e dose copanlisib infusion in non -diabetic subjects. Meal timing is added to the glucose 
management log used b y the investigator and to be continued as long as h ypergly cemia 
induced b y the copanlisib infusion persists.
Monitoring during the study
Subjects should be kept on ward as long as the post -dose glucose level is >250 mg/dL .
Table 9–6: Management of transient post -infusion glucose increases
Criteria Recommendation Suggested treatment
Asymptomatic glucose 
increases ≤ 250mg/dLDoes not generally require treatment 
with glucose lowering medicationNone
Asymptomatic glucose 
increase > 250 mg/dL-Should have repeated laboratory 
glucose determination.
-If the repeated glucose value is 
decreasing, the glucose may be 
followed without glucose lowering 
medication treatment if hydration 
status is normal as clinically 
assessed.
-Consultation with endocrinologist 
is recommended-Hydration if appropriate
Symptomatic or persisting 
glucose increases 
>250mg/dL-Hydration status should be 
clinically assessed.
-If clinical assessment is consistent 
with dehydration, fluids should be 
given as clinically appropriate 
(orally or i.v.).
-Laboratory test confirming 
increase should berepeated.
Ifthe repeated glucose value is 
persistent and/or patient is 
symptomatic and/or the hydration 
status indicates the need for 
hydration, glucose lowering 
medication should be 
administered.
-Prompt input from a diabetes 
specialist should be obtained.-Hydration if appropriate
-Rapid/ short acting insulin 
may be given for glucose 
persisting at > 250 mg/dL, 
or if the patient is 
symptomatic during the 
infusion day.
-Rapid/short acting insulin 
according to the institution 
sliding scale coverage of 
glucose persisting at 
>250mg/dL is 
recommended , with oral or 
i.v. hydration as clinically 
appropriate.
9.6.1.7.2 Treatment of arterial hypertension associated with copanlisib
Themanagement of acute arterial h ypertension following copanlisib will need to be 
individualized for each subject, but the experience in Phase I studies on copanlisib has 
suggested the benefit of dihy dropyridine calcium channel blockers (i.e. amlodipine, 
felodipine). Topical nitrates, verapamil and diltiazem (nondihy dropyridine calcium channel 
blockers) can be also considered. If arterial h ypertension ( ≥160/100 mmHg) occurs during 
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 45of 63
copanlisib i.v. infusion, the copanlisib i.v. infusion should be interrupted or slowed down, 
administration of anti -hypertensive therap y initiated and copanlisib infusion may  be resumed 
when BP has returned to <150/90 mmHg.
9.6.1.7.3 Treatment of vomiting and diarrhea
Adequate h ydration through appropriate fluid maintenance is essential for the treatment of 
diarrhea or vomiting. Anti- diarrhea medications may  be introduced if s ymptoms occur.
9.6.2 Pregnancies
A subject’s participation is to be terminated immediately  if a pregnancy  is supposed (i.e. in 
case her pregnancy  test becomes positive).
The investigator must report to the sponsor an y pregnancy occurring in a female study  subject 
during her participation in this study .  The outcome of the pregnancy  should be followed up 
carefully , and any  outcome of the mother and the child at delivery  should be reported.
The child’s health should be followed up until 1 year.
For a pregnancy  in the partner of a male study  subject, all efforts will be made to obtain 
similar information on course and outcome, subject to the partner’s consent.
For all reports, the forms provided are to be used.  The investigator shou ld submit them within 
the same timelines as an SAE.  
9.6.3 Further safety
In the event of implausible results, the laboratory  may  measure additional parameters to 
assess the quality  of the sample (e.g. clotted or hemoly zed) and to verify  the results.  The 
results from such additional anal yses may  neither be included in the clinical database of this 
study  nor evaluated further.  If the results are relevant, the investigator will be informed to 
determine follow -up activities outside of this protocol.
The foll owing safet y examinations will be performed at the time points specified in the study  
flowchart s inSection 16.1.
9.6.3.1 Body w eight and height, BMI
Body weight will be me asured by  a member of the investigator’s team under the following 
conditions:
Subject in underwear and without shoes after having emptied his/her bladder
Electronic ph ysician (column) scale with digital display , measurement units 0.1 kg
The subject’s heigh t will be measured (without shoes) to calculate the BMI.
9.6.3.2 Physical examination
The phy sical examination (by  means of inspection, palpation, auscultation) will be performed 
by a ph ysician at the study  site covering at least the organs of the cardiovascular, respiratory , 
and abdominal sy stem. The phy sical examination also includes a basic neurological 
examination.
Abnormal ph ysical examination findings are recorded either as medical history  or as AEs (see 
Section 9.6.1.1 ).
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 46of 63
9.6.3.3 Blood pressure/ pulse rate and temperature
Systolic and diastolic blood pressure and pulse rate will be measured by  a member of the 
investigator’s team under the following conditions:
Position: Supine (small pillow under head allowed) for at least 10min
Measuring site: cuff to be placed on the right/left upper arm (if possible, the same 
arm will be used for all measurements in one subject); cuff location will be 
documented
Method: osci llometric by automatic measurement device
Body temperature will be measured b y a member of the investigator’s team using alway s the 
same method according to local practice. The measured values are to be recorded in the 
electronic CRF in degree Celsius (°C ).
9.6.3.4 Electrocardiogram
A complete standard 12 -lead ECG will be recorded by  a member of the investigator’s team 
under the following conditions:
Position: supine (small pillow under head allowed) for at least 10min
Device: computerized ECG device
Automatic ca lculation of the following parameters: RR interval, pulse rate , 
P-duration, PR (PQ) interval, QRS -duration, QT / QTcB / QTcF interval 
(uncorrected and corrected QT interval according to Bazett’s / Fridericia’s
formula); corrected QT intervals of different calculation will be provided during 
data evaluation process
Evaluation of ECG by a site physician providing an overall assessment (including 
clinical relevance)
QTcB and QTcF provided by  the ECG device will be used onl y for local safety evaluation b y 
the investigator. For data anal ysis by  the sponsor, the frequency -corrected QT interval will be 
calculated according to both the formulae of Bazett (QTcB) and Fridericia (QTcF).
9.6.3.5 Laboratory examinations
Blood and urine samples will be collected b y a member of the investigator’s team.  For time 
points and parameters see Section 16.1 and Secti on 16.2 in the appendix.
9.7 Other procedures and variables
Not applicable.
9.8 Appropriateness of procedures / measurements
All PK , PD and safet y parameters, as well as the methods to measure them, are standard 
variables/ methods in clinical studies and/ or clini cal practice. They  are widely  used and 
generall y recognized as reliable, accurate and relevant.
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 47of 63
10. Statistical methods and determination of sample size
10.1 General considerations
Statistical analy sis will be performed using the software package SAS release 9.2 or higher 
(SAS I nstitute Inc., Cary , NC, USA) .
All data will be listed and summary tables will be provided where appropriate. Quantitative 
data will be described b y the following summary statistics: arithmetic mean, standard 
deviation, median, minimum and maximum. Whenever appropriate, summary  statistics will 
be provided for the original data as well as for the change versus baseline. Graphical 
illustrations will be provided where appropriate. Frequency  tables will be provided for 
qualitative data .
10.2 Anal ysis sets
Safety Analysis Set
All subjects who received at least one dose of the study  medication will be included in the 
safet y evaluation .
The PD data will also be anal yzed using the Safety  Analy sis Set.
PK Analysis Set s
All subjects with a valid PK prof ile for metformin will be included in the PK set (PKS) for 
analyzing and evaluating the PK profile of metformin.
All subjects with a valid PK profile for metformin both alone and in combination with 
copanlisib will be included in the per -protocol set (PPS) for anal yzing and evaluating the
effect of copanlisib on the PK profile of metformin .
10.3 Variables and planned statistical analyses
The primary  and secondary  variables are specified in Section 5.
Pharmacokinetic parameters are specified in Section 9.5.1.2 .
Pharmacod ynamic variables are specif ied in Section 9.5.2 .
Safety  variables are specified in Section 9.6
 Demographic and other baseline characteristics
Summary  statistics (arithmetic mean, standard deviation, median, minimum and maximum for 
quantitative variables) will be presented. Frequency  tables for qualitative data will be 
provided. Medical history  findings will be summarized using medical dictionary  for 
regulatory  activities (MedDRA) terms.
 Safety examinations
Individual listings of AEs will be provided. The incidenc e of treatment -emerge nt AEs and
drug-related AEs, respectively , will be summarized using MedDRA terms. Listings of deaths, 
SAEs and AEs leading to discontinuation will be provided.
AEs are considered to be treatment -emergent if they  start or worsen after first administration 
of study  medication up to 30 day s after end of treatment with study  medication.
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 48of 63
Quantitative data (hematology , blood chemistry , vital signs, ECG) will be summarized .
These summary  statistics will be presented for the original data as well as for the diffe rence to 
baseline. Frequency  tables will be provided for qualitative data. Laboratory  data outside the 
reference range will be listed and flagged with ‘L’ for low and ‘H’ for high. Additional tables 
with all abnormal values will be presented .
 Pharmacodynamic data
Plasma lactate levels, glucose, insulin and c- peptide will be summarized by  treatment 
conditions (Day 1 and Day 8) for the original data as well as for the difference from baseline.   
Maximum change from baseline on Day  1 and Day  8 will also be summarized.
 Pharmacokinetic data
The concentration –time data of all analy tes will be tabulated by treatment condition. The 
following statistics will be calculated for each plasma sampling point: arithmetic mean,
standard deviation and coefficient of variation (CV), geometric mean, geometric standard
deviation (re -transformed standard deviation of the logarithms) and CV, minimum, median,
maximum value and the number of measurements. Means at an y time will only  be calculated
if at least 2/3 of the individual data were measured and were above the lower limit of
quantification (LLOQ). For the calculation of the mean value a data point below LLOQ will
be substituted by  one half of this limit. In tables showing mean values, where values below
LLOQ are included in the calculation of mean values, these means will be marked.
Individual and geometric mean concentration versus time profiles of all analy tes (b y using the 
actual sampling times for individual plots and the planned sampling times for mean plots ) will 
be plotted on both linear and semi- logarithmic axes. Optionally  the amount (%) of metformin 
excreted into urine will be graphically  illustrated by  treatment condition for each sampling 
interval as well as for the whole sampling period (bar- charts f or the individual data and for the 
arithmetic means including standard deviation).
Pharmacokinetic characteristics (except t max) will be summarized by the statistics mentioned 
above. Tmaxwill be described utilizing minimum, maximum and median as well as frequency  
counts.
To investigate the primary objective of this study  regarding the effect of copanlisib on 
metformin, an exploratory analysis of variance (ANOVA) with terms of treatment co ndition 
and subject will be performed on the natural logarithmic transformation of PK parameters 
(AUC, AUC (0-24)and C max) of metformin. The estimate and 90% confidence interval of the 
Day 8 (with copanlisib) to Day  1 (without copanlisib) ratio of C max, AUC(0 -24) and AUC for 
metformin are derived b y inverse transformation of the estimates and the 90% confidence 
interval of the least squares mean differences that are obtained from the model above.
10.4 Determination of sample size
No formal statistical sample si ze estimation has been performed for this clinical study . The 
planned sample size of a minimum of 12 evaluable subjects is based on empirical 
considerations and is considered sufficient for drug -drug interaction and in humans.
Using previously  reported me tformin PK data in healthy  volunteers (7), the inter -subject 
standard deviation (SD)for log -transformed AUC and C maxwas estimated as 0.23 and 0.29 
respectivel y. To be on the conservative side for the current study , we assume the intra -subject 
SD of 0.23 for log -transformed AUC and AUC (0-24), and 0.29 for log -transformed C max. 
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 49of 63
With 12 evaluable subjects, 90% confidenc e intervals for the ratio “Day  8 (with copanlisib) / 
Day 1 (without copanlisib)” for metformin AUC and C maxare provided in Table 10–1.
Table 10–1: 90% Confidence interval for metformin with N=12
90% CI for metformin
Observed Ratio AUC (SD=0.23,
factor=1.184)Cmax(SD=0.29, 
factor=1.237)
1 (0.845, 1.184) (0.808, 1.237)
1.1 (0.929, 1.302) (0.889, 1.361)
1.2 (1.014, 1.42) (0.970, 1.484)
1.3 (1.098, 1.539) (1.051, 1.608)
CI = confidence interval
10.5 Planned interim analyses
No interim anal ysis is planned.
11. Data handling and quality assurance
11.1 Data recording
The data collection tool for this study  will be a validated electronic data capture sy stem called 
RAVE .  Subject data necessary  for anal ysis and reporting will be entered/transmitted into a 
validated database or data sy stem ( SAS).
Data required according to this protocol will be recorded b y investigational site per sonnel via 
data entry  into the internet based electronic data capture (EDC )software sy stem RAVE, 
which Bay er has licensed from Medidata Solutions Worldwide.  RAVE has been validated by  
Medidata Solutions Wo rldwide and Bayer for use in its clinical studies .  RAVE allows for the 
application of software logic to set -up data entry  screens and data checks to ensure the 
completeness and accuracy  of the data entered by  the site personnel.  Bay er extensively  
applies the logic to ensure data are complete and reflec t the clinical data requirements of the 
study .  Data queries resulting from the application of the software logic are resolved by  the 
site personnel.  The data are stored at a secure host facility  maintained b y Medidata Solutions 
Worldwide and transferred to Bay er’s internal computer sy stem via a secure Virtual Private 
Network .
All access to the RAVE system is through a password- protected security  system that is part of 
the RAVE software.  All internal Bay er and external investigator site personnel seeking 
access must go through a thorough RAVE training process before they  are granted access to 
RAVE for use in Bay er's clinical studies.  Training records are maintained.
All personnel with access to the RAVE sy stem are supported by  a Service Desk staffed with 
trained personnel to answer questions and ensure access is maintained such that data entry  can 
proceed in a timely  manner.
The RAVE Sy stem contains a sy stem -generated audit trail that captures any changes made to 
a data field, including who made the change , why the change was made and the date and time 
it was made.  This information is available both at the investigator’s site and at Bay er.  Data 
entries made in the RAVE EDC screens are supported by source documents maintained for all 
subjects enrolled in t his study .
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 50of 63
Source documentation
The site must implement processes to ensure availability  of all required source 
documentation.  A source document checklist (not part of this protocol) will be used at the 
site to identify  the source data for key  data points collected and the monitor will work with the 
site to complete this.
It is the expectation of the sponsor that all data entered into the CRF has source 
documentation available at the site.
Data recorded from screening failures
At minimum, the following data should be recorded in the CRF:
Demographic information (subject number; year of birth /age; sex; if applicable race / 
ethnicity )
Date of informed consent
Relevant inclusion/exclusion criteria
Reason for premature discontinuation
Date of last visit.
These data will be transferred to the respective database.
For screening failures with an SAE, the following data should be collected in the CRF in 
addition to the data specified above:
All information related to the SAE such as: 
- The SAE itself
-Concomitant medication
-Medical history
-Other information needed for SAE complementary  page
11.2 Monitoring
In accordance with applicable regulations, GCP, and sponsor’s/CRO’s procedures, monitors 
will contact the site prior to the start of the study to review with the sit e staff the protocol, 
study  requirements, and their responsibilities to satisfy  regulatory , ethical, and sponsor’s 
requirements.  When reviewing data collection procedures, the discussion will also include 
identification and documentation of source data it ems.
Thesponsor /designee will monitor the site activity  to verify  that the:
Data are authentic, accurate and complete.  
Supporting data may  be requested (example: blood glucose readings to support a 
diagnosis of diabetes). 
Safety  and rights of subjects are being protected
Study  is conducted in accordance with the currently  approved protocol 
(including stud y treatment being used in accordance with the protocol)
Any other study  agreements, GCP, and all applicable regulatory  requirements are 
met.
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 51of 63
The inves tigator and the head of the medical institution (where applicable) agrees to allow the 
monitor direct access to all relevant documents.
11.3 Data processing
Data will be collected as described in Section 11.1.  Clinical data management will be 
performed in accordance with applicable sponsor’s/CRO’s standards and data cleaning 
procedures.  This is applicable for data recorded on CRF as well as for data fro m other 
sources (e.g. laboratory , ECG, adjudication committees).
For data coding (e.g. AEs, medication), internationally  recognized and accepted dictionaries 
will be used.
Bioanal ytical results for PK evaluation will electronically be transferred from the 
Bioanal ytical Department to Data Management using a predefined uniform file format. Data 
Management will include these data in the corresponding SAS data repository .Data 
Management will create a transfer file containing the bioanal ytical results, demogr aphic data, 
dosing data, and actual dosing and sample collection times and will electronically  send this 
file to Clinical Science. Clinical Science will calculate the PK parameters indicated in this 
protocol as described in Section 9.5.1.2 . The finalized evaluation will electronically  be 
transferred to Data Management where all data will be included in the corresponding SAS 
data repository . All electronic file transfer proces ses will follow validated procedures.
11.4 Missing data
The occurrence of missing values is expected to be very  low in this 8-daystudy .The 
imputation of missing data is not planned. All available data will be used for statistical 
analysis. Further informat ion will be provided in the SAP.
11.5 Audit and inspection
To ensure compliance with GCP and regulatory  requirements, a member of the sponsor’s (or a 
designated CRO’s) quality  assurance unit may  arrange to conduct an audit to assess the 
performance of the study at the study  site and of the study  documents originating there.  The 
investigator/institution will be informed of the audit outcome.
In addition, inspections by regulatory  health authority  representatives and IEC(s)/I RB(s) are 
possible.  The investigator should notify  the sponsor immediately  of any  such inspection.
The investigator/institution agrees to allow the auditor or inspector direct access to all relevant 
documents and allocate his/her time and the time of his/her staff to the auditor/inspector to 
discuss findings and an y issues.  Audits and inspections may  occur at any  time during or after 
completion of the study .
11.6 Archiving
Essential documents shall be archived safel y and securel y in such a way that ensures that they  
are readil y available upon auth orities’ request.
Patient (hospital) files will be archived according to local regulations and in accordance with 
the maximum period of time permitted by the hospital, institution or private practice.  Where 
the archiving procedures do not meet the minimum timelines required b y the sponsor, 
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 52of 63
alternative arrangements must be made to ensure the availability  of the source documents for 
the required period.
The investigator/institution notifies the sponsor if the archival arrangements change 
(e.g. relocation or transfer of ownership).
The investigator site file is not to be destroy ed without the sponsor’s approval.
The contract with the investigator/institution will contain all regulations relevant for the stud y 
center.
12. Premature termination of the study
The spon sor has the right to close this study  (or, if applicable, individual segments thereof 
[e.g. treatment arms; dose steps; centers]) at an y time, which may be due but not limited to the 
following reasons: 
If risk -benefit ratio becomes unacceptable owing to, for example,
oSafety  findings from this study  (e.g. SAEs)
oResults of any  interim analy sis
oResults of parallel clinical studies
oResults of parallel animal studies 
(on e.g. toxicity , teratogenicity , carcinogenicity  or reproduction toxicity ).
If the stud y conduct (e.g. recruitment rate; drop-out rate; data qualit y; protocol 
compliance) does not suggest a proper completion of the trial within a reasonable 
time frame.
The investigator has the right to close his/her center at an y time.
For an y of the above clo sures, the following applies:
Closures should occur only  after consultation between involved parties.  Final 
decision on the closure must be in writing.
All affected institutions (e.g. IEC(s)/IRB(s); competent authority(ies); study 
center; head of stud y center) must be informed as applicable according to local 
law.
All study  materials (except documentation that has to remain stored at site) must 
be returned to the sponsor.  The investigator will retain all other documents until 
notification is given b y the sponsor for destruction.
In the event of a partial study closure, ongoing subjects, including those in post 
study  follow -up, must be taken care of in an ethical manner.
Details for individual subject ’s withdrawal can be found in Section 6.4.1 .
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 53of 63
13. Ethical and legal aspects
13.1 Investigator(s) and other study personnel
Sponsor’s Medical Expert
Name:
Title:
Address: Bayer AG
Drug Discovery , Pharmaceuticals
Clinical PD ONC I
Building P300 
13342 Berlin, German y
Phone:
Principal investigator for the Study
Name:
Title:
Address:
Phone:
Fax:
All other study  personnel not included in this section are identifi ed in a separate personnel list 
(not part of this clinical study  protocol) as appropriate.  This list will be updated as needed; an 
abbreviated version with personnel relevant for the center will be available in theinvestigator 
site file.
Whenever the term ‘investigator’ is noted in the protocol text, it may  refer to either the 
principal investigator at the site, or an appropriately  qualified, trained and delegated 
individual of the investigational site.
The principal investigator must sign the protocol signature page and must receive all required 
external approvals (e.g. health authority , ethics committee, sponsor) before subject 
recruitment may  start.  L ikewise, all amendments to the protocol must be signed by  the 
principal investigator and must have r eceived all required external approvals before coming 
into effect at the center.
13.2 Funding and financial disclosure
Funding
This study  will be funded by  its sponsor.
Financial disclosure
Each investigator (including principal and/or an y sub investigators) who is directly  involved 
in the treatment or evaluation of research subjects has to provide a financial disclosure 
PPD
PPD
PPD
PPD
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 54of 63
according to all applicable legal requirements.  All relevant documentat ion will be filed in the 
trial master file.
13.3 Ethical and legal conduct of the study
The procedures set out in this protocol, pertaining to the conduct, evaluation, and 
documentation of this study , are designed to ensure that the sponsor and investigator abi de by 
Good Clinical Practice (GCP) guidelines and the guiding principles detailed in the 
Declaration of Helsinki.  The study  will also be carried out in keeping with applicable local 
law(s) and regulation(s).
Documented approval from appropriate IEC(s)/IRB s will be obtained for all participating 
centers/countries before start of the study, according to GCP, local laws, regulations and 
organizations.  When necessary , an extension, amendment or renewal of the I EC/IRB 
approval must be obtained and also forward ed to the sponsor.  The responsible unit (e.g. 
IEC/IRB, head of the study center/medical institution) must supply  to the sponsor, upon 
request, a list of the IEC/IRB members involved in the vote and a statement to confirm that 
the IEC/I RB is organized and operates according to GCP and applicable laws and regulations.
Strict adherence to all specifications laid down in this protocol is required for all aspects of 
study  conduct; the investigator may  not modify  or alter the procedures described in this 
protoco l.  
Modifications to the study  protocol will not be implemented by  either the sponsor or the 
investigator without agreement by  both parties.  However, the investigator or the sponsor may  
implement a deviation from, or a change of, the protocol to eliminat e an immediate hazard(s) 
to the trial subjects without prior IEC/I RB/sponsor approval/favorable opinion.  As soon as 
possible, the implemented deviation or change, the reasons for it and if appropriate the 
proposed protocol amendment should be submitted to the IEC/IRB/head of medical 
institution/sponsor.  Any  deviations from the protocol must be explained and documented by  
the investigator.
Details on discontinuation of the entire stud y or parts thereof can be found in Section 12.
13.4 Subject information and consent
All relevant information on the study  will be summarized in an integrated subject information 
sheet and informed consent form provided b y the s ponsor or the study  center.  A sample 
subject information and informed consent form is provided as a document separate to this 
protocol.
Based on this subject information sheet, the investigator or designee will explain all relevant 
aspects of the stud y toeach subject , prior to his/her entry  into the study  (i.e. before an y 
examinations and procedures associated with the selection for the stud y are performed or an y 
study -specific data is recorded on study -specific forms).
The investigator will also mention that written approval of the IRB/IEC has been obtained.
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 55of 63
Each subject will be informed about the following aspects of premature withdrawal:
Each subject has the right to withdraw from the study  at any  time without any  
disadvantage and without having to prov ide reasons for this decision.  
The subject’s consent covers end -of-study  examinations as specified in the visit 
description described in Section 9.2to be conduct ed after withdrawal of consent.
The subject’s data that have been collected until the time of withdrawal will be retained 
and statistically  analy zed in accordance with the statistical anal ysis plan. 
Subject -specific data on the basis of material obtained before withdrawal may  be 
generated after withdrawal (e.g. image reading, analy sis of biological specimen such as 
blood, urine or tissues); these data would also be retained and statisticall y analyzed in 
accordance with the statistical anal ysis plan.  The s ubject has the right to object to the 
generation and processing of this post -withdrawal data. The subject’s oral objection may  
be documented in the subject’s source data.
Each subject will have ample time and opportunity  to ask questions.
Only  if the subject voluntarily  agrees to sign the informed consent form and has done so, may  
he/she enter the study .  Additionally , the investigator will personally  sign and date the form.  
The subject will receive a cop y of the signed and dated form.
The signed info rmed consent statement is to remain in the investigator site file or, if locall y 
required, in the subject’s note/file of the medical institution.
In the event that informed consent is obtained on the date that baseline study procedures are 
performed, the s tudy record or subject ’s clinical record must clearl y show that informed 
consent was obtained prior to these procedures.
The informed consent form and any other written information provided to subjects will be 
revised whenever important new information bec omes available that may  be relevant to the 
subject’s consent, or there is an amendment to the protocol that necessitates a change to the 
content of the subject information and/or the written informed consent form.  The investigator 
will inform the subject of changes in a timel y manner and will ask the subject to confirm 
his/her participation in the study  by signing the revised informed consent form.  Any  revised 
written informed consent form and written information must receive the IEC/IRB’s approval / 
favorable opinion in advance of use.
13.5 Publication policy and use of data
The sponsor has made the information regarding the study  protocol publicly  available on the 
internet at www.clinicaltrials.gov.
All data and results and all intellectual propert y right s in the data and results derived from the 
study  will be the property  of the sponsor who may  utilize them in various way s, such as for 
submission to government regulatory  authorities or disclosure to other investigators.
Regarding public disclosure of study results, the sponsor will fulfill its obligations according 
to all applicable laws and regulations.  The sponsor is interested in the publication of the 
results of every  study  it performs.
The sponsor recognizes the right of the investigator to publish t he results upon completion of 
the study .  However, the investigator, whilst free to utilize study  data derived from his/her 
center for scientific purposes, must obtain written consent of the sponsor on the intended 
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 56of 63
publication manuscript before its submiss ion.  To this end, the investigator must send a draft 
of the publication manuscript to the sponsor within a time period specified in the contract.  
The sponsor will review the manuscript promptly  and will discuss its content with the 
investigator to reach a mutually  agreeable final manuscript.
13.6 Compensation for health damage of subjects / insurance
The sponsor maintains clinical trial insurance coverage for this study  in accordance with the 
laws and regulations of the country  in which the study  is performed.
13.7 Confidentiality
All records identify ing the subject will be kept confidential and, to the extent permitted by  the 
applicable laws and/or regulations, will not be made publicly available.
Subject names will not be supplied to the sponsor.  Only  the subject number will be recorded 
in the CRF, and if the subject name appears on any  other document (e.g. pathologist report), it 
must be obliterated before a cop y of the document is supplied to the sponsor.  Study findings 
stored on a computer will be stored in accordance with local data protection laws.  As part of 
the informed consent process, the subjects will be informed in writing that representatives of 
the sponsor, IEC/I RB, or regulatory  authorities may  inspect their medical records to verify  the 
information collected, and that all personal information made available for inspection will be 
handled in strictest confidence and in accordance with local data protection laws.
If the results of the stud y are published, the subject’s identity  will remain confidentia l.
The investigator will maintain a list to enable subjects to be identified.
14. Reference list
1. Stage TB, Brøsen K, Christensen MM. A Comprehensive Review of Drug- Drug 
Interactions with Metformin. Clin Pharmacokinet. 2015 Aug;54(8):811 -24
2. Graham GG, Punt J, A rora M, Day RO, Doogue MP, Duong JK , et al. Clinical 
pharmacokinetics of metformin. Clin Pharmacokinet. 2011 Feb;50(2):81 -98
3. Gerisch M, Schwarz T, Lang D, Rohde G, Reif S, Genvresse I, et al. Pharmacokinetics 
of intravenous pan -class I phosphatidy linositol 3-kinase (PI3K) inhibitor 
[14C]copanlisib (BAY 80-6946) in a mass balance study  in healthy  male volunteers. 
Cancer Chemother Pharmacol. 2017 Sep;80(3):535 -44
4. Johansson S, Read J, Oliver S, Steinberg M, L i Y, L isbon E, et al. Pharmacokinetic 
Evaluations of the co -administrations of Vandetanib and Metformin, Digoxin, 
Midazolam, Omeprazole or Ranitidine. Clinical Pharmacokinet. 2014;53:837 -47
5. Howlett HC, Bailey  CJ. A risk -benefit assessment of metformin in ty pe 2 diabetes 
mellitus. Drug Saf. 1999 Jun;20(6):48 9-503
6. Glucophage 500 mg film coated tablets (Summary of Product Characteristics). Merck. 
Updated 19 -Jan-2017
7. Shin D, Cho YM, L ee S, Lim KS, Kim JA, Ahn JY ,et al. Pharmacokinetic and 
pharmacod ynamic interaction between gemigliptin and metformin in healthy  subjects. 
Clin Drug Investig. 2014 Jun;34(6):383 -93
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 57of 63
15. Protocol amendments
Not applicable .
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 58of 63
16. Appendices
16.1 Study flow chart
Table 16–1 provides a flow chart presenting the assessments conducted during the study ; 
Table 16–2 presents the detailed time points for the assessments conducted on Day s1 and 8.
Table 16–1: Study flow chart
Visit Screening Day -1Day 1 Day 7Day 8 EOT
Day 15- 22Follow
-upa
Informed consent X
Allocation of Screening Number X
Demographic data collection X
Height, weight, BMI X
Smoking histor y, alcohol / diet X
Medical and surgical history X
Participation in previous clinical studies X
Current and previous medication
(medication history)X X X X X X X
Physical examination X X X X (X)d
Vital signs :blood pressure, pulse rate , 
temperatureX X XbX XbX (X)d
ECG X XbXbX (X)d
Virology (HIV, HBsAg, Anti HCV -Ab) X
Urine drug screen X
Alcohol breath test X X X
Blood samples for safety (clinical 
chemistry , hematology, coagulation)X XbcXbcX (X)d
HbA1c X X
Fasting plasma glucose XbXb
Urine sample for safety
(dipstick ± sediment)X XbcXbcX (X)d
Check of inclusion / exclusion criteria X X
Metformin administ ration X X
Copanlisib administ ration X
Blood samples for PK XbXb
Urine samples for PK XbXb
Plasma glucose XbXbX
Plasma insulin XbXb
C-peptide XbXb
Plasma lactate levels XbXb
Pregnancy test (blood or urine) X Xe
Adverse events X X X X X X X
a T he follow -up will be conducted by telephone unless an in -house visit is clinically indicated.
bSee Table 16–2for individual timepoints.
cLaboratory safety tests may be performed either the day before or on 
the da y of dosing, with the exception of 
plasma glucose, which must be performed on the day o f dosing.
d T hese tests will be performed if the follow- up is conducted in -house .
ePregnancy test, if applicable, if screening pregnancy test was not within the previous 7 days.
BMI = body mass index; ECG = electrocardiogram; EOT = End of treatment; HbA1c = glycated hemoglobin;
HBsAg = Hepatitis B surface antigen; HCV-Ab = hepatitis C virus antibodies ; HIV = human immunodeficiency 
virus; PK = pharmacokinetic
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 59 of 63
Table 16–2: Schedule of evaluations :In-house treatment period
Visit D-1, D7 Day 1 and D ay 8
Relative time    (day) D00 and D 07
(relative to metformin and (hour)Pre-
dose00 00 00 01 01 02 02 03 04 06 08 10 12 1624
copan lisib administration) (minute) 00 10 30 00 30 00 30 00 00 00 00 00 00 00 00
Final el igibility check (Day 1 only) X
Study drug administration metform in X
Study drug administration copanlisib (Day 8 only )    
Blood sample safety XaX
Blood sample me tformin PK X X X X X X X X X X X X X X
Blood sample c opanlisib PK (Day 8 only) X X X X X X X X X
Urine sample metformin PK X [     ][   ][  ][  ][  ]
Urine sample safety Xa X
Pregnancy test (blood or urine) Xb
Plasma glucose X X X X X X X X X
Plasma insulin X X X X X X X X X
C-peptide X X X X X X X X X
Plasma lactate levels X X X X X X X X X
Physical examination X
Blood pressure, pulse rate , temperature X X X X X X X X X X
ECG X X X
Alcohol breath test X
Adverse events X                
Concomitant medication X                
FastcX         
D = Day .
a Laboratory safety tests may be performed either the day before or on the day of dosing, with the exception of plasma glucose, which must be performed on the day of 
dosing
b Pregnancy test, if applicable, if screening pregnancy test was not within the previous 7 days.
c Fastingshould start at least 10 hours before administration of st udy medication (drinking of water allowed) and continue until 3 hours after metformin dosing.
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 60 of 63
16.2 Laboratory analyses
Detailed information about the collection, processing, storage and shipment of the samples 
will be provided separately  e.g. sample handling sheets and/or laboratory  manual.
The amount of blood planned to be drawn during the course of this study  will be given in the 
Subject I nformation Sheet and Consent Form.
Table 16-2 provides information on the parameters to be anal yzed and indicates the
laboratories to be used.
The safet y analyses will be done by  the local laboratory  except for the urine drug screen and
alcohol breath test which will be performed at the investigational site. The laboratory  test
results will be made promptly  available to the investigator. Samples collected for non -safety
purposes may  be st ored under pre -defined conditions until final analy sis.
The time of blood samplings are given in the trial flow chart (see Section 16.1).
Refer to Section 9.2.5.2 for alimentary  restrictions imposed during the treatment period .
During the study ,drug screening or alcohol testing may  be carried out without announcement.
A listing including the total amount of blood withdrawn per subject will be stored in the study
files.
In the event of implausible results, the laboratory  may  measure additional pa rameters to 
assess the quality  of the sample (e.g. clotted or hemoly zed) and to verify  the results.  The 
results from such additional anal yses may neither be included in the clinical database of this 
study  nor evaluated further.  I f the results are relevan t, the investigator will be informed to 
determine follow -up activities outside of this protocol.
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 61 of 63
Table 16–3 : Parameters of laboratory analyses
Parameters (by category) Sample destination
Hematology: Local laboratory
Leukocytes (white blood cell count), er ythroc ytes, 
hemoglobin, hematocrit, mean corpuscular volume (MCV), 
mean corpuscular hemoglobin (MCH), reticulocytes 
(absolute), platelets, neutrophils, eosinophils, basophils, 
lymphocy tes, monocy tes
Other:
Glycated hemoglobin (HbA1c) (screening and EOT only)
Clotting status : Local laboratory
Prothrombin time ( sec), reagent -independent prothrombin 
ratio (INR, international normalized ratio), activated partial 
thromboplastin time
Serum chemistry: Local laboratory
Creatinine, sodium, potassium, calcium, chloride, am ylase, 
lipase, total protein, albumin,
creatine kinase, cholesterol (total, high -density lipoprotein 
[HDL]-/low density lipoprotein [ LDL]-cholesterol), 
triglycerides, C -reactive protein
Liver function: Local laboratory
Alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), gamma -glutam yl transferase ( GGT), glutamate 
dehy drogenase, alkaline phosphatase, lactate 
dehy drogenase, total bilirubin
Virology: Local laboratory
HBsAg, antiHCV -Ab, anti -HIV 1+2
Urinalysis –dip stick: To be performed at study site
pH-value, urobilinogen, erythrocytes, hemoglobin, protein, 
ketone, bilirubin, nitrite, glucose
Urinalysis –sediment: Local laboratory
Crystals
Urine drug screen : To be performed at study site
Amphetamines, barbiturates, benzodiazepines, 
cannabinoids, cocaine, methadone, methamphetamine, 
opiates, tric yclic antidepressives, phencyclidin
Alcohol breath test To be performed at study site
Pharmacokinetic analyses: Analytical laboratory
Parameters arespecified in Section 9.5.1
Pharmaco dynamic analyses: To be performed at study site
Plasma glucose, plasma insulin, C-peptide, plasma lactate 
levels; details are provided in Section 9.5.2
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 62 of 63
16.3 Concomitant medication NOT permitted (or to be taken with caution) 
during screening and treatment phase of the study
CYP3A4 inhibitors and inducers are NOT permitted during this study.
Strong CYP3A 4 inhibitors Boceprevir, clarithrom ycin, conivaptan, grapefruit juice, indinavir, 
itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, 
nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, 
telithrom ycin, voriconazole, atazanavir, tipranavir, troleoandom ycin, 
elvitegravir, danoprevir, conivaptan, boceprevir, suboxone and 
cobicistat
Strong CYP3A 4 inducers Avasimibe, carbamaz epine, mitotane, phenobarbital, phenytoin, 
rifabutin, rifampin (rifampicin), St. John's wort (hypericum perforatum) 
and enzalutamide
FDA. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. 
Available online: 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugIntera
ctionsL abeling/ucm093664.
FDA. Clinical Drug Interaction Studies — Study Design, Data Anal ysis, and Clinical 
Implications. Guidance for Industry . Draft Guidance (2017). Available from: 
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/uc
m292362.pdf
Clinical Study  Protocol
No.  BAY 80 -6946 / 19951
15 May 2018 Version 1 Page: 63 of 63
16.4 Estimation of glomerular filtration rate (eGFR) using modification of
diet in renal disease
In accordance with established nephrology  practice and guidelines, renal function at baseline 
will be assessed b y means of the eGFR, calculated using the abbreviated MDRD Study 
equation.
This equation of 4 variables (serum creatinine level, age, sex, and ethnicit y) is recommended 
by the National Kidney  Foundation for use in individuals 18 y ears or older.  The formula is as 
follows:
GFR (mL/min/1.73 m2) = k × (S cr)-1.154× (Age)-0.203× (0.742 if female) × (1.212 if African 
American),
where
k=175 if serum creatinine was measured b y methods calibrated to an IDMS reference method.
For the purpose of the study , it is recommended to use the Bay er-verified calculator 
(preferred) or online MDRD GFR calculator at http://mdrd.com/